<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults - López-Briz, E - 2022 | Cochrane Library</title> <meta content="Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults - López-Briz, E - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008462.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults - López-Briz, E - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008462.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008462.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults" name="citation_title"/> <meta content="Eduardo López-Briz" name="citation_author"/> <meta content="La Fe University Hospital" name="citation_author_institution"/> <meta content="lopez_edubri@gva.es" name="citation_author_email"/> <meta content="Vicente Ruiz Garcia" name="citation_author"/> <meta content="La Fe University Hospital" name="citation_author_institution"/> <meta content="Juan B Cabello" name="citation_author"/> <meta content="Hospital General Universitario de Alicante" name="citation_author_institution"/> <meta content="Sylvia Bort-Martí" name="citation_author"/> <meta content="HIPRA" name="citation_author_institution"/> <meta content="Rafael Carbonell Sanchis" name="citation_author"/> <meta content="Sagunt Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD008462.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008462.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008462.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008462.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Catheter-Related Infections [epidemiology]; *Central Venous Catheters; Hemorrhage [chemically induced]; *Heparin [adverse effects]; Randomized Controlled Trials as Topic; *Saline Solution [adverse effects]; Sepsis; Thrombocytopenia [chemically induced]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008462.pub4&amp;doi=10.1002/14651858.CD008462.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6iOnQIUh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008462\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008462\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008462.pub4",title:"Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults",firstPublishedDate:"Jul 18, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008462.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008462.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008462.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008462.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008462.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008462.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008462.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008462.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008462.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008462.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13358 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008462.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-sec-0073"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/appendices#CD008462-sec-0078"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/supinfo/CD008462StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/supinfo/CD008462StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information#CD008462-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Eduardo López-Briz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information#CD008462-cr-0005">Vicente Ruiz Garcia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information#CD008462-cr-0006">Juan B Cabello</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information#CD008462-cr-0007">Sylvia Bort-Martí</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information#CD008462-cr-0008">Rafael Carbonell Sanchis</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information/en#CD008462-sec-0083">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008462.pub4">https://doi.org/10.1002/14651858.CD008462.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008462-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008462-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008462-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008462-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008462-abs-0009">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008462-abs-0001" lang="en"> <section id="CD008462-sec-0001"> <h3 class="title" id="CD008462-sec-0001">Background</h3> <p>Intermittent locking of central venous catheters (CVCs) is undertaken to help maintain their patency and performance. There are systematic variations in care: some practitioners use heparin (at different concentrations), whilst others use 0.9% sodium chloride (normal saline). This review looks at the effectiveness and safety of intermittent locking with heparin compared to normal saline, to see if the evidence establishes whether one is better than the other. This is an update of an earlier Cochrane Review. </p> </section> <section id="CD008462-sec-0002"> <h3 class="title" id="CD008462-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of intermittent locking of CVCs with heparin versus normal saline in adults to prevent occlusion. </p> </section> <section id="CD008462-sec-0003"> <h3 class="title" id="CD008462-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was 20 October 2021. </p> </section> <section id="CD008462-sec-0004"> <h3 class="title" id="CD008462-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials in adults ≥ 18 years of age with a CVC that compared intermittent locking with heparin at any concentration versus normal saline. We excluded studies on infants and children from this review. </p> </section> <section id="CD008462-sec-0005"> <h3 class="title" id="CD008462-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were occlusion of CVCs and duration of catheter patency. Our secondary outcomes were CVC‐related bloodstream infections and CVC‐related colonisation, mortality, haemorrhage, heparin‐induced thrombocytopaenia, CVC‐related thrombosis, number of additional CVC insertions, abnormality of coagulation profile and allergic reactions to heparin. We used GRADE to assess the certainty of evidence for each outcome. </p> </section> <section id="CD008462-sec-0006"> <h3 class="title" id="CD008462-sec-0006">Main results</h3> <p>We identified one new RCT with 30 participants for this update. We included a total of 12 RCTs with 2422 participants. Data for meta‐analysis were available from all RCTs. We noted differences in methods used by the included studies and variation in heparin concentrations (10 to 5000 IU/mL), time to follow‐up (1 to 251.8 days), and the unit of analysis used (participant, catheter, line access). Five studies included ICU (intensive care unit) patients, two studies included oncology patients, and the remaining studies included miscellaneous patients (chronic kidney disease, haemodialysis, home care patients, etc.). </p> <p><b>Primary outcomes</b> </p> <p>Overall, combined results may show fewer occlusions with heparin compared to normal saline but this is uncertain (risk ratio (RR) 0.70, 95% confidence interval (CI) 0.51 to 0.95; 10 studies; 1672 participants; low‐certainty evidence). We pooled studies that used participant or catheter as the unit of analysis. </p> <p>We carried out subgroup analysis by unit of analysis. No clear differences were detected after testing for subgroup differences (P = 0.23). </p> <p>We found no clear evidence of a difference in the duration of catheter patency with heparin compared to normal saline (mean difference (MD) 0.44 days, 95% CI ‐0.10 to 0.99; 6 studies; 1788 participants; low‐certainty evidence). </p> <p><b>Secondary outcomes</b> </p> <p>We found no clear evidence of a difference in the following outcomes: CVC‐related bloodstream infections (RR 0.66, 95% CI 0.08 to 5.80; 3 studies; 1127 participants; very low‐certainty evidence); mortality (RR 0.76, 95% CI 0.44 to 1.31; 3 studies; 1100 participants; very low‐certainty evidence); haemorrhage (RR 1.54, 95% CI 0.41 to 5.74; 3 studies; 1197 participants; very low‐certainty evidence); or heparin‐induced thrombocytopaenia (RR 0.21, 95% CI 0.01 to 4.27; 3 studies; 443 participants; very low‐certainty evidence). </p> <p>The main reasons for downgrading the certainty of evidence for the primary and secondary outcomes were unclear allocation concealment, suspicion of publication bias, imprecision and inconsistency. </p> </section> <section id="CD008462-sec-0007"> <h3 class="title" id="CD008462-sec-0007">Authors' conclusions</h3> <p>Given the low‐certainty evidence, we are uncertain whether intermittent locking with heparin results in fewer central venous catheter occlusions than intermittent locking with normal saline in adults. Low‐certainty evidence suggests that heparin may have little or no effect on catheter patency duration. Although we found no evidence of differences in safety (CVC‐related bloodstream infections, mortality, or haemorrhage), the combined studies were not powered to detect rare adverse events such as heparin‐induced thrombocytopaenia. Further research conducted over longer periods would reduce the current uncertainties. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008462-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008462-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008462-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008462-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008462-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008462-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008462-abs-0005">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008462-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008462-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008462-abs-0002" lang="en"> <h3>Does heparin locking prevent blocking of central venous catheters in adults when compared to locking with normal saline? </h3> <p><b>Key message</b> </p> <p>We did not find clear evidence of a difference between heparin and normal saline solution (sterile solution of salt in water) in preventing central venous catheter blockages (occlusions), or in the length of time catheters remained unblocked, or in the number of side effects such as infections, death, bleeding, etc. Further well‐designed, large‐scale studies are required to reduce uncertainties. </p> <p><b>Why is this question important?</b> </p> <p>Central venous catheters are tubes (also called 'lines') that must be temporarily placed into the veins of patients whose veins need to be accessed regularly for medical reasons. These are inserted into the great vessels leading to the heart. While not in use, a fluid is injected into the catheter until it is next used to avoid blood clots that can block the catheter. This is called locking catheters. Replacement of catheters adds to the cost of care, may delay treatment, and poses an additional risk of catheter‐related adverse events to the patient. The catheter may also become infected, resulting in bloodstream infections. Fluids used for locking are heparin or normal saline. Heparin, which is an anticoagulant, is used to prevent clotting of the blood. It may also help to prevent the catheters from blocking; however, it can also cause bleeding, allergic reactions, and a drop in the number of platelets in the blood. This has raised the question whether heparin is better than saline to avoid blockages, and how safe each method is. </p> <p><b>What did we do?</b> </p> <p>We searched for randomised controlled trials that assessed whether locking catheters with heparin was more effective in reducing the risk of blocking and infections compared to normal saline. In randomised controlled trials, the treatments people receive are decided at random and these give the most reliable evidence about treatment effects. </p> <p><b>What we did find?</b> </p> <p>We found one new study for this update. In total, we included 12 studies with 2422 people. Five studies included ICU patients, two studies included cancer patients, and the remaining studies included miscellaneous patients (haemodialysis, home care patients, etc.). We cannot conclude that locking catheters with heparin prevents blocking better than flushing with normal saline. We saw little or no difference in the length of time the catheter remained unblocked or in the numbers of side effects between heparin or saline use. </p> <p><b>How certain are we with the evidence?</b> </p> <p>When comparing heparin with saline, the certainty of the evidence of the results ranged from very low to low due to the design of the studies and because the overall result included the likelihood of both benefit and harm. </p> <p><b>How up to date is the evidence?</b> </p> <p>This Cochrane review updates our previous evidence. The evidence is current to 20 October 2021. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008462-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008462-sec-0073"></div> <h3 class="title" id="CD008462-sec-0074">Implications for practice</h3> <section id="CD008462-sec-0074"> <p>Given the low‐certainty evidence, we are uncertain whether intermittent locking with heparin results in fewer central venous catheter occlusions than intermittent locking with normal saline in adults. Low‐certainty evidence suggests that heparin may have little or no effect on catheter patency duration. Although we found no evidence of differences in safety (CVC‐related bloodstream infections, mortality, or haemorrhage), the combined studies were not powered to detect rare adverse events such as heparin‐induced thrombocytopaenia. We are uncertain about the effects of heparin compared to normal saline, and review findings should be interpreted with caution. </p> </section> <h3 class="title" id="CD008462-sec-0075">Implications for research</h3> <section id="CD008462-sec-0075"> <p>Better designed large‐scale randomised controlled trials are needed to definitively establish or rule out a net benefit of locking with heparin versus normal saline; these trials should also explore effectiveness in different patient groups, such as patients under haemodialysis or those with onco‐haematological malignancies. Trials should report the outcome using both the participant and the catheter as units of analysis to allow evidence to be combined more consistently. Occlusions and adverse events must be the focus of future studies, and we suggest at least one month of follow‐up. In addition, assessment by type of line (i.e. dialysis/apheresis versus peripherally inserted central catheter (PICC) or versus other) is important. Addressing the question of harm from rare events requires high‐quality prospective cohort studies with sufficient follow‐up. Decision analytical modelling incorporating the costs of heparin and normal saline and the probabilities and costs of alteplase use and catheter replacement may also help to establish the thresholds required to conclude which method is the most appropriate and efficient choice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008462-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008462-sec-0008"></div> <div class="table" id="CD008462-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus normal saline solution locking for prevention of occlusion in central venous catheters in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Heparin versus normal saline solution locking for prevention of occlusion in central venous catheters in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with CVCs<br/><b>Settings:</b> hospital<br/><b>Intervention:</b> heparin<br/><b>Comparison:</b> normal saline solution (0.9% NaCl) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with normal saline</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with h<b>eparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Occlusion of CVC</b> </p> <p><b>(combining participant, and catheter as unit of analysis)</b> </p> <p>Blood withdrawing<br/>Follow‐up: 1 to 231 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.70</b> <br/>(0.51 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1672 participants,</p> <p>1025 catheters<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heparin may reduce the rate of CVC occlusion when compared to normal saline, NNTB: 42 (95% CI 32 to 252). </p> <p>Considering only participant as unit of analysis:</p> <p>RR 0.79 (95% CI 0.58 to 1.08; 7 studies, 1672 participants)</p> <p>Considering only catheter as unit of analysis:</p> <p>RR 0.53 (95% CI 0.29 to 0.95; 3 studies, 1025 catheters), NNTB: 35 (95% CI 23 to 326)</p> <p>Considering only line access as unit of analysis:</p> <p>RR 1.06 (95% CI 0.84 to 1.33; 2 studies, 6835 lines accessed)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/><b>(62 to 86)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Duration of catheter patency</b> </p> <p><b>(days; combining participant and catheter as unit of analysis)</b> </p> <p>Blood withdrawing<br/>Follow‐up: 3 to 180 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1788<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in duration of catheter patency was shown ‐ less than 1 day longer with heparin locking </p> <p>Considering only participant as unit of analysis:</p> <p>MD 0.66 (95% CI ‐0.66 to 1.97; 4 studies, 1036 participants)</p> <p>Considering only catheter as unit of analysis:</p> <p>MD 0.40 (95% CI ‐0.20 to 0.99; 2 studies, 752 catheters)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean catheter patency in the normal saline group was</p> <p>9 days (8.36 to 9.7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean catheter patency in the heparin group was <b>0.44 days more</b> <br/><b>(‐0.1 less to 0.99 more)</b> than in the normal saline group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>CVC‐related bloodstream infections (positive microbiological culture, participant as unit of analysis)</b> </p> <p>Follow‐up: 22 to 180 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.66</b><br/>(0.08 to 5.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1127<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in CVC‐related bloodstream infections between locking methods was shown. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> <br/><b>(0 to 212)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 17 to 180 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b> <br/>(0.44 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1100<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in mortality between locking methods was shown.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> <p><b>(24 to 57)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Haemorrhage from any site</b><br/>Follow‐up: 1 to 180 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 1.54 </p> <p>95% CI 0.41 to 5.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1197<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in haemorrhage between locking methods was shown.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/><b>(‐10 to 11)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Heparin‐induced thrombocytopaenia</b> </p> <p>Follow‐up: 7 to 22 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.21</b> </p> <p>(0.01 to 4.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>443</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in HIT between locking methods was shown. Studies are likely to be underpowered to detect low adverse events. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> <p><b>(0 to 38)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>**<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>CVC</b> : central venous catheter; <b>HIT</b> : heparin‐induced thrombocytopaenia; <b>MD</b> : mean difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> We downgraded the certainty of evidence by two levels, i.e. one level for risk of bias due to suspicion of publication bias (see <a href="./full#CD008462-fig-0001">Figure 1</a>) and one level due to imprecision.<br/><sup>2</sup> We downgraded the certainty of evidence by two levels, i.e. one level for risk of bias due to unclear allocation concealment and one level due to imprecision.<br/><sup>3</sup> We downgraded the certainty of evidence by three levels, i.e. two levels due to imprecision (low number of events and CIs were very wide) and one level due to inconsistency.<br/><sup>4</sup> We downgraded the certainty of evidence by three levels, i.e. one level due to risk of bias and two levels due to imprecision (low number of events and CIs were very wide). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD008462-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Occlusion of CVCs, outcome: 1.1 All studies" data-id="CD008462-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Occlusion of CVCs, outcome: 1.1 All studies</p> </div> </div> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008462-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008462-sec-0009"></div> <section id="CD008462-sec-0010"> <h3 class="title" id="CD008462-sec-0010">Description of the condition</h3> <p>Vascular access devices (VADs) are commonly used in healthcare. They encompass a wide range of devices that include, among others, central venous catheters (CVCs). A CVC is a catheter with a tip that lies within the proximal third of the superior vena cava, the right atrium, or the inferior vena cava. Catheters can be inserted through a peripheral vein or a proximal central vein, most commonly the internal jugular, subclavian, or femoral vein. Four types of CVCs are available: non‐tunnelled catheters, tunnelled catheters (e.g. Hickman catheters, tunnelled dialysis catheters), peripherally inserted central catheters (PICCs), and totally implantable ports (Port‐a‐cath) (<a href="./references#CD008462-bbs2-0242" title="SmithRN . Central venous catheters. British Medical Journal2013;347:f6570. [DOI: 10.1136/bmj.f6570]">Smith 2013</a>). </p> <p>In the United States, more than five million CVCs are inserted every year (<a href="./references#CD008462-bbs2-0235" title="MerrerJ , De JongheB , GolliotF , LefrantJY , RaffyE , BarreE , et al, French Catheter Study Group in Intensive Care. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. Journal of the American Medical Association2001;286(6):700-7.">Merrer 2001</a>), leading to approximately 15 million central line days per year in intensive care units (ICUs) (<a href="./references#CD008462-bbs2-0234" title="MermelLA . Prevention of intravascular catheter-related infections. Annals of Internal Medicine2000;132(5):391-402.">Mermel 2000</a>). CVCs allow measurement of haemodynamic variables that cannot be measured accurately by non‐invasive methods (although some minimally invasive methods are now available), and they allow delivery of blood, medication, and nutritional support that cannot be given safely through peripheral venous catheters. Unfortunately, use of CVCs is associated with adverse events. Among them, mechanical complications during insertion (arterial puncture, haematoma, and pneumothorax) in 5% to 29% (<a href="./references#CD008462-bbs2-0214" title="EisenLA , NarasimhanM , BergerJS , MayoPH , RosenMJ , SchneiderRF . Mechanical complications of central venous catheters. Journal of Intensive Care Medicine2006;21(1):40-6.">Eisen 2006</a>; <a href="./references#CD008462-bbs2-0231" title="McGeeDC , GouldMK . Preventing complications of central venous catheterization. New England Journal of Medicine2003;348(12):1123-33.">McGee 2003</a>), infectious complications in 5% to 26% (<a href="./references#CD008462-bbs2-0235" title="MerrerJ , De JongheB , GolliotF , LefrantJY , RaffyE , BarreE , et al, French Catheter Study Group in Intensive Care. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. Journal of the American Medical Association2001;286(6):700-7.">Merrer 2001</a>; <a href="./references#CD008462-bbs2-0237" title="RaadI , DarouicheR , DupuisJ , Abi-SaidD , GabrielliA , HachemR , et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Annals of Internal Medicine1997;127(4):267-74.">Raad 1997</a>; <a href="./references#CD008462-bbs2-0246" title="VeenstraDL , SaintS , SahaS , LumleyT , SullivanSD . Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. Journal of the American Medical Association1999;281(3):261-7.">Veenstra 1999</a>), and thrombosis in 2% to 26% (<a href="./references#CD008462-bbs2-0227" title="LeeDH , WarkentinTE . Frequency of heparin-induced thrombocytopenia. In: WarkentinTE , GreinacherA , editors(s). Heparin-Induced Thrombocytopenia. 4th edition. New York: Informa Healthcare, 2007:67-116.">Lee 2007</a>) are the most common. Almost all of catheter occlusions are thrombotic. Non‐thrombotic occlusions represent only a small percentage and are caused mainly by medication, lipids deposits, mineral precipitates or mechanical obstructions (<a href="./references#CD008462-bbs2-0223" title="JacobsBR . Central venous catheter occlusion and thrombosis. Critical Care Clinics2003;19(3):489-514.">Jacobs 2003</a>). </p> <p>To some extent, thrombi are formed on CVCs during the first few hours of use in the form of fibrin tail, fibrin sheath, intraluminal occlusion, or mural thrombus (<a href="./references#CD008462-bbs2-0224" title="JonkerMA , OsterbyKR , VermeulenLC , KleppinSM , KudskKA . Does low-dose heparin maintain central venous access device patency? A comparison of heparin versus saline during a period of heparin shortage. Journal of Parenteral and Enteral Nutrition2010;34(4):444-9. [PMID: 20631392]">Jonker 2010</a>), and thrombosis of large vessels occurs after long‐term catheterisation (<a href="./references#CD008462-bbs2-0245" title="ValerioD , HusseyJK , SmithFW . Central vein thrombosis associated with intravenous feeding - a prospective study. Journal of Parenteral and Enteral Nutrition1981;5(3):240-2.">Valerio 1981</a>). The incidence of CVC‐related thrombosis varies depending on the patient's condition, catheter tip position and diameter, side and technique of insertion, and the chemical structure and nature of the infusate, among other factors (<a href="./references#CD008462-bbs2-0247" title="VersoM , AgnelliG . Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. Journal of Clinical Oncology2003;21(19):3665-75.">Verso 2003</a>). CVC‐related thrombosis represents an important source of morbidity and mortality among affected patients, not only for its inherent risks but also because thrombus creates a medium for bacterial proliferation that promotes infection (<a href="./references#CD008462-bbs2-0234" title="MermelLA . Prevention of intravascular catheter-related infections. Annals of Internal Medicine2000;132(5):391-402.">Mermel 2000</a>). Pulmonary embolism, a severe medical condition, occurs in approximately 15% of patients with CVC‐related upper extremity deep venous thrombosis (<a href="./references#CD008462-bbs2-0212" title="BurnsKE , McLarenA . A critical review of thromboembolic complications associated with central venous catheters. Canadian Journal of Anaesthesia2008;55(8):532-41.">Burns 2008</a>). </p> <p>To avoid thrombus formation in CVCs, clinicians are currently applying several measures with different levels of success. Among others, heparin‐locking catheters (<a href="./references#CD008462-bbs2-0210" title="BishopL . Aftercare and management of central venous access devices. In: HamiltonH , BodenhamA , editors(s). Central Venous Catheters. 1st edition. Chichester: Wiley &amp; Blackwell, 2009:221-37.">Bishop 2009</a>), heparin‐bonded catheters (<a href="./references#CD008462-bbs2-0241" title="ShahPS , ShahVS . Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD002772. [DOI: 10.1002/14651858.CD002772.pub3]">Shah 2008</a>), systemic heparinisation with unfractionated heparin or with low molecular weight heparin (<a href="./references#CD008462-bbs2-0239" title="RandolphAG , CookDJ , GonzalesCA , AndrewM . Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest1998;113(1):165-71.">Randolph 1998b</a>), anticoagulation with warfarin (<a href="./references#CD008462-bbs2-0209" title="BernMM , LokichJJ , WallachSR , BotheA , BenottiPN , ArkinCF , et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Annals of Internal Medicine1990;112(6):423-8.">Bern 1990</a>), or administration of alteplase or urokinase, as in <a href="./references#CD008462-bbs2-0080" title="HemmelgarnBR , MoistLM , LokCE , TonelliM , MannsBJ , HoldenRM , et al, for the Prevention of Dialysis Catheter Lumen Occlusion with rt-PA versus Heparin (PreCLOT) Study Group. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. NEJM2011;364(4):303-12. ">Hemmelgarn 2011</a> and <a href="./references#CD008462-bbs2-0161" title="Ray CE Jr, ShenoySS , McCarthyPL , BroderickKA , KaufmanJA . Weekly prophylactic urokinase instillation in tunneled central venous access devices. Journal of Vascular and Interventional Radiology1999;10(10):1330-4. ">Ray 1999</a>, respectively, may be used. Heparin locking is the most commonly used procedure. According to some trial authors, the use of heparin may be justified with some types of VADs when they are not used frequently (<a href="./references#CD008462-bbs2-0210" title="BishopL . Aftercare and management of central venous access devices. In: HamiltonH , BodenhamA , editors(s). Central Venous Catheters. 1st edition. Chichester: Wiley &amp; Blackwell, 2009:221-37.">Bishop 2009</a>), but the efficacy of this practice remains unproven (<a href="./references#CD008462-bbs2-0229" title="López-BrizE , Ruiz-GarciaV . Effectiveness of heparin versus NaCl 0.9% in central venous catheter flushing. A systematic review [Heparina frente a cloruro sódico 0.9% para mantener permeables los catéteres venosos centrales. Una revisión sistemática]. Farmacia Hospitalaria2005;29(4):258-64.">López‐Briz 2005</a>). </p> </section> <section id="CD008462-sec-0011"> <h3 class="title" id="CD008462-sec-0011">Description of the intervention</h3> <p>Heparin locking essentially consists of filling the lumens of CVCs with solutions of unfractionated heparin of varying strength. To rinse out the catheter after every use the catheter needs to be flushed. Flushing helps keep the catheter clean. It also prevents blood clots from blocking the catheter. </p> </section> <section id="CD008462-sec-0012"> <h3 class="title" id="CD008462-sec-0012">How the intervention might work</h3> <p>People that have CVCs are at risk of vascular thrombosis via vessel wall injury (during catheter placement), hypercoagulability, and alterations in normal blood flow. The balance between haemostatic systems producing thrombi and fibrinolytic systems dissolving them regulates blood vessel lumen patency, but placement of a CVC can alter this fine‐tuned process, leading to a persistent thrombotic state. Catheter composition also plays a role in this thrombotic situation, allowing adsorption of fibrin and fibrinogen on its surface, thereby worsening the problem (<a href="./references#CD008462-bbs2-0223" title="JacobsBR . Central venous catheter occlusion and thrombosis. Critical Care Clinics2003;19(3):489-514.">Jacobs 2003</a>). The anticoagulant properties of heparin have led clinicians to use heparin flushes in an attempt to prevent thrombus formation and to prolong the duration of catheter patency between uses. However, this physiopathological rationale may be wrong when applied to peripheral venous catheters, for which no benefit in using heparin locking versus normal saline solution (a crystalloid solution that contains 9.0 g of sodium chloride (NaCl) per litre of water) locking has been demonstrated, as two published systematic reviews have independently shown (<a href="./references#CD008462-bbs2-0215" title="GoodeCJ , TitlerM , RakelB , OnesDS , KleiberC , SmallS , et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nursing Research1991;40(6):324-30.">Goode 1991</a>; <a href="./references#CD008462-bbs2-0238" title="RandolphAG . An evidence-based approach to central venous catheter management to prevent catheter-related infection in critically ill patients. Critical Care Clinics1998;14(3):411-21.">Randolph 1998a</a>). </p> </section> <section id="CD008462-sec-0013"> <h3 class="title" id="CD008462-sec-0013">Why it is important to do this review</h3> <p>Bishop and colleagues reported in 2009 that heparin locking of catheters is a standard practice in the maintenance of CVCs (<a href="./references#CD008462-bbs2-0210" title="BishopL . Aftercare and management of central venous access devices. In: HamiltonH , BodenhamA , editors(s). Central Venous Catheters. 1st edition. Chichester: Wiley &amp; Blackwell, 2009:221-37.">Bishop 2009</a>), but the effectiveness of this practice so far has not been established in a systematic review. Moreover, variation in nursing practice is considerable because current guidelines provide conflicting recommendations about locking frequency and heparin concentration and volume (<a href="./references#CD008462-bbs2-0236" title="MitchellMD , AndersonBJ , WilliamsK , UmscheidCA . Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. Journal of Advanced Nursing2009;65(10):2007-21.">Mitchell 2009</a>). A survey conducted in ICUs in the United States shows that 64.6% of respondents used normal saline and 31% used heparin (<a href="./references#CD008462-bbs2-0243" title="SonaC , PrenticeD , SchallomL . National survey of central venous catheter flushing in the intensive care unit. Critical Care Nurse2012;32(1):e12-9.">Sona 2012</a>). The concentrations of heparin most commonly used were 100 IU/mL (37.5%) and 10 IU/mL (29.7%), and the most common intervals for locking catheters were every eight hours and after each use (74.4%). No information is available on CVC maintenance practices in other countries, so could clinical expertise be the guiding principle on this topic? </p> <p>There are reasons to think that heparin locking catheters might be helpful. This makes pathophysiological sense. One systematic review studied the benefits of heparin in central venous and pulmonary artery catheters (<a href="./references#CD008462-bbs2-0239" title="RandolphAG , CookDJ , GonzalesCA , AndrewM . Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest1998;113(1):165-71.">Randolph 1998b</a>). This paper showed that prophylactic systemic heparin decreases catheter‐related venous thrombosis (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.23 to 0.78) and bacterial colonisation of CVCs (RR 0.18, 95% CI 0.06 to 0.60) and may decrease catheter‐related bacteraemia (RR 0.26, 95% CI 0.07 to 1.03). <a href="./references#CD008462-bbs2-0239" title="RandolphAG , CookDJ , GonzalesCA , AndrewM . Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest1998;113(1):165-71.">Randolph 1998b</a> included combined data from trials using several doses of systemic prophylactic heparin, including unfractionated heparin (treatment regimens of 1 IU/kg, 3 IU/kg, 50 IU q12h, and 5000 IU intermittently), low molecular weight heparin (2500 IU given subcutaneously daily), or heparin‐bonded catheters and did not include trials that provided periodic flushing of CVCs with heparin. </p> <p>However, there are also potential harms associated with heparin use. Heparin‐induced thrombocytopaenia (HIT), a severe immunological drug reaction known to cause arterial and venous thromboembolism, raises serious concerns regarding the use of heparin (<a href="./references#CD008462-bbs2-0248" title="WarkentinTE . Clinical picture of heparin-induced thrombocytopenia. In: WarkentinTE , GreinacherA , editors(s). Heparin-Induced Thrombocytopenia. 4th edition. New York: Informa Healthcare, 2007:21-66.">Warkentin 2007</a>). Exposure of surgical patients to unfractionated heparin for longer than four days implies an overall risk of HIT of 2.6% (<a href="./references#CD008462-bbs2-0230" title="MartelN , LeeJ , WellsPS . Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood2005;106(8):2710-5.">Martel 2005</a>). A recent paper highlights an incidence of HIT in the USA of 0.76% in patients treated with therapeutic doses of non‐fractionated heparin and less than 0.1% with prophylactic doses, leading to an amputation rate of 3 to 4% (<a href="./references#CD008462-bbs2-0218" title="GruelY , De MaistreE , PouplardC , MullierdF , SuseneS , RoulletghS , et al. Diagnosis and management of heparin-induced thrombocytopenia. Anesthesia Critical Care and Pain Medicine2020;39(2):291-310.">Gruel 2020</a>). </p> <p>This adverse effect of heparin treatment is a common late‐onset complication that can develop five or more days after initiation of the drug. Another potential harm that may be associated with heparin use is the incidental administration of a heparin bolus through a catheter line intended for heparin locking. </p> <p>From an economic point of view, avoiding heparin locking would represent a very important cost savings (<a href="./references#CD008462-bbs2-0243" title="SonaC , PrenticeD , SchallomL . National survey of central venous catheter flushing in the intensive care unit. Critical Care Nurse2012;32(1):e12-9.">Sona 2012</a>). Another systematic review estimated yearly savings of USD109 million to USD218 million when peripheral venous lines were flushed with normal saline instead of heparin (<a href="./references#CD008462-bbs2-0215" title="GoodeCJ , TitlerM , RakelB , OnesDS , KleiberC , SmallS , et al. A meta-analysis of effects of heparin flush and saline flush: quality and cost implications. Nursing Research1991;40(6):324-30.">Goode 1991</a>). </p> <p>In summary, the effectiveness of heparin locking of CVCs has not yet been demonstrated, and wide systematic variations in both guideline recommendations and practice have surrounded its use. Moreover, use of heparin is not free of risk and has a considerable economic impact. We developed a protocol and performed a systematic review about this topic (<a href="./references#CD008462-bbs2-0252" title="López-BrizE , Ruiz GarciaV , CabelloJB , Bort-MartiS , Carbonell SanchisR , BurlsA . Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD008462. [DOI: 10.1002/14651858.CD008462]">López‐Briz 2010</a>; <a href="./references#CD008462-bbs2-0253" title="López-BrizE , Ruiz GarciaV , CabelloJB , Bort-MartiS , Carbonell SanchisR , BurlsA . Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD008462. [DOI: 10.1002/14651858.CD008462.pub2]">López‐Briz 2014</a>). This is the second update of our review first published in 2014. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008462-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008462-sec-0014"></div> <p>To evaluate the benefits and harms of intermittent locking of central venous catheters with heparin versus normal saline in adults to prevent occlusion. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008462-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008462-sec-0015"></div> <section id="CD008462-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008462-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled trials (RCTs) of heparin locking versus normal saline locking of central venous catheters (CVCs) in adults. We excluded studies when researchers used alternative methods of randomisation (quasi‐randomised), such as alternate days of the week, odd and even numbers, dates of birth, hospital numbers, or historical controls. </p> </section> <section id="CD008462-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies of adults 18 years of age or older with a CVC. We excluded from this review studies on infants and children, as they are the topic of another Cochrane review (<a href="./references#CD008462-bbs2-0211" title="BradfordNK , EdwardsRM , ChanRJ . Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long-term central venous catheters in infants and children. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD010996. [DOI: 10.1002/14651858.CD010996.pub3]">Bradford 2020</a>). </p> </section> <section id="CD008462-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Interventions included intermittent locking with heparin (any dose with or without systemic drugs ‐ except systemic heparin) compared with normal saline solution. All locking protocols were accepted for inclusion. </p> </section> <section id="CD008462-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008462-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008462-list-0001"> <li> <p>Occlusion of CVCs (defined as inability to infuse fluids through the catheter because of blockage) </p> </li> <li> <p>Duration (in days) of catheter patency</p> </li> </ul> </p> </section> <section id="CD008462-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008462-list-0002"> <li> <p>Episodes of CVC‐related bloodstream infections; CVC‐related bloodstream infections are defined as the presence of positive blood cultures from both the catheter and peripheral veins and fever or chills in absence of other infection sources (<a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>). </p> </li> <li> <p>Episodes of CVC‐related colonisation; CVC‐related colonisation is defined as the presence of micro‐organisms in the CVC only and not at another sterile site. </p> </li> <li> <p>Mortality</p> </li> <li> <p>Haemorrhage from any site in the body</p> </li> <li> <p>Heparin‐induced thrombocytopaenia (HIT) (development of thrombocytopaenia after heparin locking of a CVC in an adult with a previously normal platelet count after exclusion of all other causes of thrombocytopaenia, along with a positive antibody test) </p> </li> <li> <p>CVC‐related thrombosis (determined by colour‐coded Doppler ultrasonography, venography, computerised tomography, or magnetic resonance venography) </p> </li> <li> <p>Number of additional CVC insertions</p> </li> <li> <p>Abnormality of coagulation profile</p> </li> <li> <p>Allergic reactions to heparin</p> </li> </ul> </p> <p>Outcomes were assessed using the description and definitions used by the included studies and reported using the time points reported by the studies, generally at the end of the study period. </p> </section> </section> </section> <section id="CD008462-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We applied no restriction on language of publication.</p> <section id="CD008462-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for randomised controlled trials and controlled clinical trials without language, publication year or publication status restrictions: </p> <p> <ul id="CD008462-list-0003"> <li> <p>The Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web);</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL; via the Cochrane Register of Studies Online (CRSO); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE); </p> </li> <li> <p>Embase Ovid;</p> </li> <li> <p>CINAHL EBSCO.</p> </li> </ul> </p> <p>We developed search strategies for other databases from the search strategy designed for MEDLINE. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008462-bbs2-0228" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Lefebvre 2022</a>)). Search strategies for major databases are provided in <a href="./appendices#CD008462-sec-0079">Appendix 1</a>. </p> <p>We searched the following trials registries:</p> <p> <ul id="CD008462-list-0004"> <li> <p>The World Health Organization International Clinical Trials Registry Platform (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> <p>The most recent searches were carried out on 20 October 2021.</p> </section> <section id="CD008462-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of relevant studies identified through the electronic searches in order to find missing studies. </p> </section> </section> <section id="CD008462-sec-0026"> <h3 class="title" id="CD008462-sec-0026">Data collection and analysis</h3> <section id="CD008462-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ELB and VRG) independently read the abstract and, if necessary, the full text of potentially relevant references, to identify studies that needed to be further examined. We excluded letters, editorials, commentaries, reviews, and lectures that did not contain original research data. We contacted authors of unpublished and ongoing trials to obtain further information. When differences in opinion arose, we consulted a third review author (RCS). </p> </section> <section id="CD008462-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (ELB, VRG, and RCS) independently extracted data regarding populations, interventions, relevant outcomes, funding source and declarations of interest from the study authors, using the standard Cochrane Vascular forms for dichotomous data and continuous data. We contacted study authors to obtain additional data, if necessary (<a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). </p> </section> <section id="CD008462-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in included studies by using standardised criteria from Cochrane for the following (<a href="./references#CD008462-bbs2-0220" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1.">Higgins 2011</a>). </p> <p> <ul id="CD008462-list-0005"> <li> <p>Adequacy of random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> </section> <section id="CD008462-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratio (RR) with 95% confidence interval (CI) and number needed to treat for an additional beneficial outcome (NNTB) to measure any effect on dichotomous variables (i.e. occlusion of CVCs, mortality, adverse events, etc.). We calculated NNTB values from the RR according to the formula NNTB (or number needed to treat for an additional harmful outcome (NNTH)) = 1/ACR*(1‐RR), for which ACR is the assumed control risk (<a href="./references#CD008462-bbs2-0233" title="McQuayHJ , MooreRA . Using numerical results from systematic reviews in clinical practice. Annals of Internal Medicine1997;126(9):712-20.">McQuay 1997</a>). </p> </section> <section id="CD008462-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis differed between studies and was either the participant or catheter or line access (i.e. each time a line of a CVC is used to administer drugs, blood, etc.). We performed analysis separately for each different unit of analysis for outcomes that could have been influenced by the unit of analysis (occlusions and patency), if sufficient data were available. The main analyses stratified studies by the unit of analysis type, but we also reported the main results irrespective of the unit of analysis. For secondary outcomes, when considering adverse effects, we used the participant as the denominator for analysis. </p> </section> <section id="CD008462-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the principal investigators of two studies to request additional data (<a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). These study authors provided relevant data that were later published. </p> </section> <section id="CD008462-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We attempted to explain relevant clinical, methodological, or statistical heterogeneity using forest plots, and we quantified heterogeneity using the I² statistic (<a href="./references#CD008462-bbs2-0221" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). Thresholds for interpretation of I² can be misleading in that the importance of inconsistency depends on several factors. <a href="./references#CD008462-bbs2-0221" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a> prepared the following rough guide to interpretation. </p> <p> <ul id="CD008462-list-0006"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: shows considerable heterogeneity.</p> </li> </ul> </p> <p>We considered I<sup>2</sup> values &gt; 50% to indicate significant heterogeneity. </p> </section> <section id="CD008462-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias using funnel plots, since we found a sufficient numbers of studies. </p> </section> <section id="CD008462-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We summarised data statistically, if possible. We performed statistical analysis according to the statistical guidelines referenced in the current version of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008462-bbs2-0221" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). We used Review Manager for review production and data analysis (<a href="./references#CD008462-bbs2-0240" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We used a random‐effects model, even though I² values were low because, although the same drug was used across trials (heparin), we noted clear clinical heterogeneity in the study methods applied (i.e. different doses with systemic heparin or not, different follow‐up times, different kinds of patients, etc.). </p> </section> <section id="CD008462-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses for each different unit of analysis for the primary outcomes (participant, catheter or line access). The incidence of CVC‐related thrombosis varies depending on clinical background of the participants (suffering malignancies or other onco‐haematological diseases, admitted to intensive care units, on dialysis, etc.), CVC implantation site, CVC type, and perfusion‐related factors. We planned to perform subgroup analyses to take these factors into account, if sufficient data were available. </p> </section> <section id="CD008462-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses to explore the robustness of results by investigating the influence of the following factors on effect size for occlusions. </p> <p> <ul id="CD008462-list-0007"> <li> <p>Published or unpublished studies.</p> </li> <li> <p>Methodological quality of studies. We explored quality of studies according to the risk of bias of the allocation concealment. </p> </li> <li> <p>Weight of different studies. We categorised most weighted studies as those with more than 30% of total weight. </p> </li> <li> <p>Different measures of effect size (odds ratio (OR) and RR).</p> </li> </ul> </p> </section> <section id="CD008462-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created <a href="./full#CD008462-tbl-0001">summary of findings Table 1</a> to present the results for the comparison of heparin versus normal saline intermittent locking for prevention of occlusion in central venous catheters in adults. We used GRADEpro GDT software to present the main findings of the review (gradepro.org) (<a href="./references#CD008462-bbs2-0217" title="GRADEpro GDT. Version accessed August 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.">GRADEproGDT 2015</a>), and assessed the certainty of the evidence as high, moderate, low, or very low, based on within‐study risk of bias, directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias (<a href="./references#CD008462-bbs2-0219" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal2008;336(7650):924-6.">Guyatt 2008</a>). We judged the outcomes of CVC occlusion, duration of catheter patency, CVC‐related bloodstream infections, mortality, haemorrhage, and heparin‐induced thrombocytopaenia to be the most clinically relevant to healthcare professionals and patients. For each outcome, we calculated assumed control intervention risks from the mean number of events reported in the control groups of selected studies. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008462-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008462-sec-0039"></div> <section id="CD008462-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD008462-sec-0041"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD008462-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD008462-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram 2021" data-id="CD008462-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram 2021</p> </div> </div> </div> </section> <section id="CD008462-sec-0042"> <h4 class="title">Included studies</h4> <p>One new study met the inclusion criteria for this update (<a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>), bringing the number of included studies to 12, involving a total of 2422 patients (<a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>; <a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a>; <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>; <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a>; <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). See <a href="./references#CD008462-sec-0091" title="">Characteristics of included studies</a>. </p> <p><a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a> performed an RCT in 100 participants from the Respiratory Intensive Care Unit with triple lumen CVC. This study compared heparin (3 mL, 10 IU/ mL) versus normal saline (10 mL) flushes every eight hours. The primary outcome of the study was lumen non‐patency, defined as inability to both withdraw blood and flush through a lumen, and the unit of analysis was the participant. Researchers reached the conclusion of lumen non‐patency after the following interventions: (1) if the lumen could not be flushed, the participant was repositioned and the flush re‐attempted; and (2) if the lumen still could not be flushed, the syringe was changed and the flush was re‐attempted. Investigators assessed the secondary outcome, HIT, using daily platelet count starting on day 4 from the time of giving heparin flushes to all participants in the heparin group. </p> <p><a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a> was a single‐blinded randomised controlled trial with 100 participants with chronic kidney disease. Researchers randomly assigned participants to locking with heparin (1000 IU) versus normal saline. The unit of analysis was the participant. Only three in the heparin group and one in the normal saline group withdrew. We sent a letter to study authors to request more information, but they did not respond to our request. Length of follow‐up was 24 hours. </p> <p><a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a> conducted a single‐centre randomised study in 102 adult participants with single‐lumen peripherally inserted central catheters (PICCs) with luer‐activated devices. Trial authors used a random block design with allocation concealment to randomly assign participants to receive normal saline or heparin lock flush (100 USP U/mL). The main outcome studied was occlusion rate, and the secondary outcome was duration of PICCs (in days). The unit of analysis was the participant for occlusion rate as well as for patency. All participants completed the study (50 in the normal saline group and 52 in the heparin group). </p> <p><a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a> was a multicentre, open‐label randomised trial with 430 oncology participants. Investigators randomly assigned participants to locking with heparin 5 mL (50 IU) versus normal saline 5 mL. Trial authors used the participant as the unit of analysis for occlusion. Study authors reported 5% withdrawals from the normal saline group and 2.5% from the heparin group without providing details. </p> <p><a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> conducted a randomised controlled open‐label non‐inferiority trial in 802 participants older than one year scheduled for first insertion of a totally implantable venous access device (TIVAD) through the superior vena cava (SVC) system, with an onco‐haematological malignancy and with sufficient life expectancy to complete the planned follow‐up of 180 days at the study centre. After randomisation via computerised random number generation, researchers assigned 398 participants to receive a normal saline lock and 404 to receive a heparin lock in a non‐blinded manner. Although participants were randomly assigned, the main unit of analysis was the number of catheters accessed. However, the study authors provided us with additional information about occlusions per participant. Participants who had difficulties with aspiration through the catheter were registered. Investigators considered outcomes of withdrawal occlusion, catheter‐related bloodstream infections, and catheter duration within 180 days (unit of analysis ‐ participant), as well as adverse events. The study authors also provided data on thrombosis, and mortality. As this study included adults and children, we also requested data for the adult participants only. The study author responded as follows: "Only 3.5% of patients were &lt;18 years old; given that small number we didn't perform any sub analysis. Moreover we don't presume any difference in results between adults and peds" [sic]. </p> <p><a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a> conducted a double‐blinded RCT in 84 participants from the intensive care unit. This study compared a flush of 3 mL of heparin (10 IU/mL) versus normal saline locking. The main outcome was CVC patency, and the unit of analysis chosen was the participant. We requested additional information from study authors, but they did not respond to our request. Follow‐up period was 21 days. </p> <p><a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> performed a single‐centre, open‐label, randomised controlled clinical trial in adult participants with an inserted double‐lumen CVC. This study compared a flush of 20 mL of normal saline versus a flush of 20 mL of normal saline followed by locking with 2 mL heparin (1000 IU/mL). Researchers used low molecular weight heparin at 8 IU/kg/h during each haemodialysis session. They randomly allocated 48 participants to the normal saline (26) or heparin group (22). They studied the outcomes: days of catheter survival and thrombotic occlusion (both considered the participant as the unit of analysis), as well as coagulation analytical parameters such as activated coagulation time, activated partial thromboplastin time, and prothrombin time. </p> <p><a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a> performed a RCT in 30 patients from the blood and bone transplantation unit. The study was not blinded. Fifteen were flushed with normal saline and 15 with different concentrations of heparin according to the lines (triple or double lumen). In addition, every line was flushed depending on the type of line. Outcomes of interest were patency and safety. The unit of analysis was line access. </p> <p><a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a> performed a single RCT on 90 participants from home care and tried to find the most effective locking solution for maintenance of PICCs. This study compared three arms: 10 mL of normal saline, 5 mL of low‐dose heparin (10 IU/mL), and 3 mL of high‐dose heparin (100 IU/mL). The main outcome was the development of patency‐related complications (sluggishness, occlusions, etc.), and researchers used the participant as the unit of analysis. One participant in the normal saline group and one in the high‐dose heparin group withdrew. We sent a letter to study authors to request more information and they kindly provided us with the protocol of study. </p> <p><a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> carried out a two‐phase clinical trial in a polyvalent ICU. Participants were adults with multiple pathological processes in whom a three‐lumen CVC had been inserted. Researchers used a registered software program for randomisation. However, the study was not blinded. In the first phase, trialists compared two concentrations of heparin (20 IU/mL and 100 IU/mL), establishing patency at 24 hours after catheter implantation and at discharge. In the second phase, 125 participants were randomised to each group and heparin at a concentration of 100 IU/mL was compared to normal saline. Patency was assessed at 24 hours, at 72 hours, and at discharge. Only this second phase fulfilled our inclusion criteria. Although study authors randomised 125 to each group, 95 CVCs were assessed (38 in the heparin group and 57 in the normal saline group) for occlusion rates and mean days of catheter duration, using the catheter as the unit of analysis for both. </p> <p><a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a> studied 99 three‐lumen CVCs inserted into 91 adult participants locked with one of the following solutions: normal saline, heparin (5000 IU/mL), or vitamin C (200 mg/mL). Researchers assigned catheters randomly (using a list of random numbers prepared by the study authors) to one of three groups. They assessed patency every two days to a maximum of 20 days. Study outcomes included thrombotic obstruction and catheter survival, with the catheter used as the unit of analysis. </p> <p><a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a> conducted a single‐centre study wherein researchers randomly assigned patients in the ICU with a newly placed three‐ or four‐lumen CVC (simple randomisation, sequence concealed) to be flushed with normal saline or with heparin (10 IU/mL every 8 hours). Among the randomly assigned participants, 295 had at least one lumen with a minimum of two flushes, resulting in 326 catheters (170 allocated to the normal saline group and 156 to the heparin group) with 709 lumens (395 in the normal saline group and 314 in the heparin group). The primary outcome was lack of lumen patency (unit of analysis was the catheter). Secondary outcomes included rates of loss of blood return, flush failure, HIT, and catheter‐related bloodstream infection. </p> </section> <section id="CD008462-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 12 additional studies for this update (<a href="./references#CD008462-bbs2-0087" title="IRCT51660. Comparison of the effect of intravenous catheter washing with heparin, normal saline, and taurolock solution on phlebitis severity. www.irct.ir/trial/51660 (first received 20 October 2020). [IRCT20151228025732N56]">IRCT20151228025732N56</a>; <a href="./references#CD008462-bbs2-0088" title="IRCT20190325043107N4. Comparison of the effect of heparin saline and normal saline on keeping open the pathway of peripheral or peripheral venous catheters in cancer patients. trialsearch.who.int/?TrialID=IRCT20190325043107N4 (first received 21 April 2019). [IRCT20190325043107N4]">IRCT20190325043107N4</a>; <a href="./references#CD008462-bbs2-0089" title="IRCT44454. Comparing the effects of flushing and saline lock on phlebitis and patency time of peripheral intravenous catheters in patients admitted to the medical department. irct.ir/trial/44454 (first received 31 January 2020). [IRCT20191218045773N2]">IRCT20191218045773N2</a>; <a href="./references#CD008462-bbs2-0095" title="KaewsangsaiC , PongsittisakW . The efficacy and safety of sodium bicarbonate versus heparin for locking solution of non-tunnelled non-cuffed dialysis catheter: a randomized control study (ESBL-study). Nephrology2021;26((Suppl 1)):12-3. ">Kaewsangsai 2021</a>; <a href="./references#CD008462-bbs2-0109" title="LiuF , LiaoT , WangQ , TaoY . Evaluation of a novel flushing protocol for a peripherally inserted central catheter (PICC) in the neurological intensive care unit: a prospective randomized study. National Medical Journal of India2018;31(1):5-7. ">Liu 2018</a>; <a href="./references#CD008462-bbs2-0147" title="NCT02923830. Maintaining patency in BioFlo implanted port catheters with saline only flushes. clinicaltrials.gov/ct2/show/NCT02923830 (first received 30 September 2016). ">NCT02923830</a>; <a href="./references#CD008462-bbs2-0165" title="RobertsLN , AryaR , HoganBJ . Comment on comparison of three transfusion protocols prior to central venous catheterisation in patients with cirrhosis; a randomised controlled trial. Journal of Thrombosis and Haemostasis2020;18(3):754-5. [DOI: 10.1111/jth.14737]">Roberts 2020</a>; <a href="./references#CD008462-bbs2-0167" title="SainiV , SamraT , AhujaN , SethiS . A prospective randomized study to evaluate safety and efficacy of heparin topical solution (1000 IU/mL) compared to heparin topical gel (200 IU/g) in prevention of infusion-associated phlebitis. Indian Journal of Pharmacology2018;50(6):344-9. ">Saini 2018</a>; <a href="./references#CD008462-bbs2-0174" title="RBR-3ht499. Effect of heparin to prevent obstruction of the Hickman® catheter. ensaiosclinicos.gov.br/rg/RBR-3ht499 (first received 3 July 2017). [https://ensaiosclinicos.gov.br/rg/RBR-3ht499]SilvaSR , ReichembachMT , PontesL , KusmaS . Heparin solution in the prevention of occlusions in Hickman catheters: a randomized clinical trial. Revista Latino-Americana de Enfermagem2021;29(2021):e3385. [DOI: 10.1590/1518-8345.3310.3385. eCollection 2021]">Silva 2021</a>; <a href="./references#CD008462-bbs2-0180" title="TCTR20200610003. Comparison [of] the permanent catheter loss rate between 7.5% sodium bicarbonate and heparin lock in chronic hemodialysis patients. thaiclinicaltrials.org/show/TCTR20200610003 (first received 10 June 2020). ">TCTR20200630005</a>; <a href="./references#CD008462-bbs2-0192" title="WathanavasinW , PhannajitJ , PoosoonthronsriM , LewsuwanS , TanateerapongP , JongthanakornK , et al. A randomized controlled trial of comparative effectiveness between sodium bicarbonate and heparin as a locking solution for tunnelled central venous catheters among haemodialysis patients. Canadian Journal of Kidney Health and Disease2021;8:20543581211046077. [DOI: 10.1177/20543581211046077]">Wathanavasin 2021</a>; <a href="./references#CD008462-bbs2-0196" title="WoutersY , CausevicE , KlekS , GroenewoudH , WantenGJ . Use of catheter lock solutions in patients receiving home parenteral nutrition: a systematic review and individual-patient data meta-analysis. Journal of Parenteral and Enteral Nutrition2020;44(7):1198-209. ">Wouters 2020</a>). </p> <p>The total number of excluded studies in the current review is 189. We excluded these studies for the following reasons: </p> <p> <ul id="CD008462-list-0008"> <li> <p>Studies did not meet the criteria established for intervention (heparin) or comparison (normal saline). </p> </li> <li> <p>Studies focussed on peripheral catheters.</p> </li> <li> <p>Studies focussed on arterial catheters.</p> </li> <li> <p>Studies did not provide data stratified by arterial or venous catheters.</p> </li> <li> <p>Studies were in fact protocols of data unpublished/published.</p> </li> </ul> </p> <p>We excluded some studies for more than one reason.</p> <p>See the <a href="./references#CD008462-sec-0092" title="">Characteristics of excluded studies</a> section for further details. </p> <section id="CD008462-sec-0044"> <h5 class="title">Ongoing studies</h5> <p>We identified six new studies as ongoing (<a href="./references#CD008462-bbs2-0202" title="ChiCTR1800018391. The effect of different concentrations of heparin sealing liquid on thrombosis after peripherally inserted central catheter catheterization in malignant tumor patients: a prospective, single-blind, randomized, controlled study. chictr.org.cn/showproj.aspx?proj=30808 (first received 14 September 2018). [DOI: 10.21203/rs.2.54/v1]">ChiCTR1800018391</a>; <a href="./references#CD008462-bbs2-0203" title="CTRI/2021/04/033007. A randomized controlled trial on comparison of normal saline with heparin for maintaining patency of central venous catheters in intensive care unit patients. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/04/033007 (first received 22 April 2021). [033007]">CTRI/2021/04/033007</a>; <a href="./references#CD008462-bbs2-0204" title="IRCT20190905044704N1. The effect of intermediate dose of heparin solution in the prevention of central vein catheter occlusion on ICU admitted patients. irct.ir/trial/57908 (first received 19 August 2021). [IRCT20190905044704N1]">IRCT20190905044704N1</a>; <a href="./references#CD008462-bbs2-0205" title="JPRN-UMIN000033713. The maintenance of central venous catheters and atrial blood pressure catheters. trialsearch.who.int/Trial2.aspx?TrialID=JPRN-UMIN000033713 (first received 1 November 2018). [JPRN-UMIN000033713]">JPRN‐UMIN000033713</a>; <a href="./references#CD008462-bbs2-0206" title="NCT02354118. Maintaining patency in implanted port catheters. clinicaltrials.gov/ct2/show/NCT02354118 (first received 3 February 2013). [NCT0235411823]">NCT02354118</a>; <a href="./references#CD008462-bbs2-0207" title="NCT05029596. Heparin versus normal saline in peripherally inserted central catheter lines. clinicaltrials.gov/ct2/show/NCT05029596 (first received 31 August 2021). [NCT05029596]">NCT05029596</a>). See <a href="./references#CD008462-sec-0093" title="">Characteristics of ongoing studies</a> for further details. </p> </section> </section> </section> <section id="CD008462-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD008462-fig-0003">Figure 3</a> and <a href="#CD008462-fig-0004">Figure 4</a> show the risk of bias according to the methodological quality of included trials. </p> <div class="figure" id="CD008462-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008462-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD008462-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008462-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD008462-sec-0046"> <h4 class="title">Allocation</h4> <p>Eight studies provided sufficient information on random sequence generation, so we assessed the risk of bias for these studies as low (<a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a>; <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a>; <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). In four studies, the information provided about the sequence generation process was either insufficient or undisclosed, so we judged them to be at unclear risk of bias (<a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>; <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a>). </p> <p>Eight studies provided insufficient information about allocation concealment, so we assessed the risk of selection bias for these studies as unclear (<a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>; <a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a>; <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>; <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>). <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> reported a method of closed envelopes, but it remains unclear whether the envelopes were opaque or sealed to conceal information. <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> concealed the allocation sequence from researchers who enrolled participants by using sequentially numbered participant cards stored in a separate room; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a> stated that the allocation sequence was concealed from the researcher enrolling participants; <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a> used a web‐based method to conceal allocation; and <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a> used a sequentially numbered, opaque sealed envelope method, so we assessed these studies as having low risk of selection bias. </p> </section> <section id="CD008462-sec-0047"> <h4 class="title">Blinding</h4> <p>Nine studies were open‐label or did not blind participants or research staff to the intervention received. We rated these studies as having a unclear risk of performance and detection bias (<a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>; <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>; <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). </p> <p><a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a> and <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a> used single‐blinding design, and we classified the risk of performance and detection bias as unclear for both. </p> <p><a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a> was at low risk of bias as both participants and researchers were unaware of which locking fluid was used (the solution was made up by nurses). However, neither occlusion nor patency was likely to be influenced by lack of blinding. We judged that the secondary outcomes, namely, CVC‐related thrombosis, episodes of CVC‐related bloodstream infections and colonisation, numbers of additional CVC insertions, mortality, coagulation profile, HIT, and allergic reactions to heparin and haemorrhage, were also unlikely to be influenced by lack of blinding. </p> </section> <section id="CD008462-sec-0048"> <h4 class="title">Incomplete outcome data</h4> <p>We considered <a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a> (two in heparin groups and one in saline group withdrew), <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a> (no withdrawals), <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a> (five participants in heparin group and 10 in saline group withdrew), <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a> (no withdrawals), <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a> (no withdrawals), <a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a> (no withdrawals), and <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a> (no withdrawals), to have a low risk of attrition bias because missing outcome data were either none or few and were balanced in numbers across intervention groups, and reasons for missing data were similar across groups. </p> <p>Researchers from <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a> and <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> reported attrition or exclusions insufficiently to permit judgement, and information about the number of catheters losing patency in each treatment group was lacking in <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>. In <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>, one patient was excluded from the normal saline group and two from the heparin group, because of incomplete flushing records; furthermore, in <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>, the presence of occlusion was evaluated several times per day resulting in a huge number of observations; hence, the impact of losing a participant could not be properly estimated. We judged these three studies as having an unclear risk of attrition bias. </p> <p>We rated both <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> and <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> as having a high risk of bias. <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> reported 40% withdrawals in the heparin group (9/22) and 30% in the normal saline group (8/26) and provided unclear reasons for withdrawal. <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> reported a withdrawal rate of 69.6% (87/125) in the heparin group and 54.4% (68/125) in the normal saline group; the main reason for withdrawal was cancellation of the procedure (74/125 and 52/125, respectively). </p> </section> <section id="CD008462-sec-0049"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a>, <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>, and <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a> reported all expected outcomes, so we rated these studies as having a low risk of selective reporting bias. The remaining studies were at unclear risk owing to lack of available protocols or insufficient information retrieved from researchers (<a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a>; <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>; <a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>; <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). </p> </section> <section id="CD008462-sec-0050"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>, <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a> and <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a> were rated at low risk of bias. <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> might be underpowered as researchers analysed only 38 and 57 catheters per group, but the predetermined sample size was 185 catheters per group; trialists stopped the study early for 74 and 52 catheters in the heparin and normal saline groups, respectively, but did not provide the reason for this. Therefore, we rated the risk of other bias as high. In <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>, 3.5% of participants were children and study authors did not perform separate analyses; therefore we rated the risk of other bias as unclear. In the remaining studies, the risk of other bias was also rated as unclear because there was not enough information to permit a low‐risk judgement of bias. </p> </section> </section> <section id="CD008462-sec-0051"> <h3 class="title" id="CD008462-sec-0051">Effects of interventions</h3> <p>See: <a href="./full#CD008462-tbl-0001"><b>Summary of findings 1</b> Heparin versus normal saline solution locking for prevention of occlusion in central venous catheters in adults</a> </p> <section id="CD008462-sec-0052"> <h4 class="title">Primary outcomes</h4> <section id="CD008462-sec-0053"> <h5 class="title">Occlusion of CVCs</h5> <p>Ten studies (1672 participants, 1025 catheters and 6835 lines accessed) reported on occlusion of CVCs using either the participant, the catheter or the line access as the unit of analysis. We pooled results in the overall meta‐analysis for the unit of analysis catheter and participants (<a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a>; <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a>; <a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>; <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). We used a Mantel‐Haenszel (M‐H) random‐effects model because of clinical heterogeneity between the studies. Results showed fewer occlusions with heparin (RR 0.70, 95% CI 0.51 to 0.95; P = 0.02; <a href="./references#CD008462-fig-0005" title="">Analysis 1.1</a>). We calculated the number needed to treat for an additional beneficial outcome (NNTB) as 42 (95% CI 32 to 252) using the calculator from Chris Cates' web page (<a href="http://www.nntonline.net/visualrx/" target="_blank">nntonline.net/visualrx</a>). </p> <p>The funnel plot that we created for this outcome suggested that the risk of publication bias was present (<a href="./full#CD008462-fig-0001">Figure 1</a>). We judged the certainty of the evidence for this outcome to be low. We downgraded the certainty of evidence by one level for risk of bias due to suspicion of publication bias and one more level for imprecision. </p> <p>Seven studies (1672 participants) used the participant as the unit of analysis (<a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>; <a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a>; <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a>). We noted no clear evidence of an effect upon pooling this subgroup only (RR 0.79, 95% CI 0.58 to 1.08; P = 0.15; <a href="./references#CD008462-fig-0005" title="">Analysis 1.1</a>). NNTB was 37 (95% CI ‐96 to 19). We judged the certainty of evidence to be low. We downgraded the certainty of evidence by one level for risk of bias due to unclear allocation concealment and by one more level for imprecision. </p> <p>Three studies with 1025 participants used the catheter as the unit of analysis (<a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). Results demonstrated a favourable effect of heparin (RR 0.53, 95% CI 0.29 to 0.95; P = 0.03; <a href="./references#CD008462-fig-0005" title="">Analysis 1.1</a>). NNTB was 35 (95% CI 23 to 326). We judged the certainty of evidence to be low. We downgraded the certainty of evidence by two levels, i.e. one for risk of bias due to unclear allocation concealment and one for imprecision. </p> <p>Testing for subgroup differences did not indicate a difference between the subgroups (P = 0.23). </p> <p>Two studies used line access as the unit of analysis (<a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>). These studies included 6835 observations and showed no differences in the number of occlusions between heparin and normal saline locking (RR 1.06, 95% CI 0.84 to 1.33; P = 0.15; <a href="./references#CD008462-fig-0006" title="">Analysis 1.2</a>) (NNTB 417 (95% ‐76 to 157)). We judged the certainty of evidence as low. We downgraded the certainty of evidence by two levels, i.e. one for risk of bias due to unclear allocation concealment and one for imprecision. Despite lack of blinding in these trials, we decided not to further downgrade certainty because obstruction is a categorical outcome and unlikely to be influenced by blinding. The authors of one study (<a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>) provided data for unit of analysis participants and for unit of analysis line accessed. </p> <p>We did not pool data for unit of analysis: participants, catheters and line access as we judged this to not be clinically appropriate. For line access, the presence of occlusion was evaluated several times per day resulting in a huge number of observations in a very low number of participants. </p> </section> <section id="CD008462-sec-0054"> <h5 class="title">Duration (in days) of catheter patency</h5> <p>We pooled six studies with 1788 participants (using the participant or the catheter as the unit of analysis) and analysed results for catheter patency duration (<a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>, <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). Overall, data showed no clear difference in this outcome between heparin and normal saline groups for duration of patency in days (mean difference (MD) 0.44, 95% CI ‐0.10 to 0.99; P = 0.11; <a href="./references#CD008462-fig-0007" title="">Analysis 2.1</a>). We judged the certainty of evidence as low. We downgraded the certainty of evidence by one level for risk of bias due to unclear allocation concealment and by one more level for imprecision. </p> <p>Four studies with 1036 participants used the participant as the unit of analysis for catheter patency duration (<a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>). We detected no clear differences between heparin and normal saline groups (MD 0.66, 95% CI ‐0.66 to 1.97; P = 0.33; <a href="./references#CD008462-fig-0007" title="">Analysis 2.1</a>). We judged the certainty of evidence as low. We downgraded the certainty of evidence by one level for risk of bias due to unclear allocation concealment and by one more level for imprecision. </p> <p>Two studies with 752 participants used the catheter as the unit of analysis for catheter patency duration (<a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). We observed no clear differences between heparin and normal saline groups (MD 0.40, 95% CI ‐0.20 to 0.99; P = 0.19; <a href="./references#CD008462-fig-0007" title="">Analysis 2.1</a>). We judged the certainty of evidence as low. We downgraded the certainty of evidence by one level for risk of bias due to unclear allocation concealment and by one more for imprecision. </p> <p>Testing for subgroup differences did not indicate a difference between the subgroups (P = 0.72). </p> <p>No studies reporting on this outcome used line access as the unit of analysis.</p> </section> </section> <section id="CD008462-sec-0055"> <h4 class="title">Secondary outcomes</h4> <p>See additional <a href="#CD008462-tbl-0002">Table 1</a>. </p> <div class="table" id="CD008462-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>CVC‐related thrombosis</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>CVC‐related bloodstream infections</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Mortality</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>HIT</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NS</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/150</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CVC: central venous catheter<br/>H: heparin<br/>HIT: heparin‐induced thrombocytopaenia<br/>NR: not reported<br/>NS: normal saline (0.9% NaCl) </p> </div> </div> <section id="CD008462-sec-0056"> <h5 class="title">Episodes of CVC‐related bloodstream infections</h5> <p>Three studies (1127 participants) reported on CVC‐related bloodstream infections (<a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). Analysis showed no clear evidence of an effect with heparin use (RR 0.66, 95% CI 0.08 to 5.80; P = 0.71; <a href="./references#CD008462-fig-0008" title="">Analysis 3.1</a>). In <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>, four participants in the normal saline group experienced episodes of CVC‐related bloodstream infection compared with none in the heparin group (data received via personal communication with study authors). The study authors treated all four participants using non–antibiotic‐impregnated catheters. This difference was not statistically significant (Chi² = 2.180; P = 0.14; Yates correction applied). <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> found catheter‐related bloodstream infections in 2 out of 404 cases (0.5%) in the normal saline group and in 6 out of 398 cases (1.5%) in the heparin group (P = 0.18). Only one case of central line‐associated bloodstream infection in the arm of normal saline was found in <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a>. We judged the certainty of evidence to be very low. We downgraded the certainty of evidence by two levels due to imprecision (low number of events and CIs were very wide) and one more due to inconsistency. </p> </section> <section id="CD008462-sec-0057"> <h5 class="title">Episodes of CVC‐related colonisation</h5> <p>None of the studies assessed reported on CVC‐related colonisation.</p> </section> <section id="CD008462-sec-0058"> <h5 class="title">Mortality</h5> <p>Three studies (1100 participants) reported on mortality (<a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>). Results showed no evidence of an effect (RR 0.76, 95% CI 0.44 to 1.31; P = 0.42; <a href="./references#CD008462-fig-0009" title="">Analysis 3.2</a>). <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> did not report any deaths, <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> reported three deaths (two in the heparin group and one in the normal saline group, without significant differences), and <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> reported 48 deaths (28 in the normal saline group and 20 in the heparin group; P = 0.255). No other included studies reported mortality. We judged the certainty of evidence to be very low. We downgraded the certainty of evidence by three levels, i.e. one level due to risk of bias and two levels due to imprecision (low number of events and CIs were very wide). The NNTB for mortality was not calculated as there was no evidence of an effect. </p> </section> <section id="CD008462-sec-0059"> <h5 class="title">Haemorrhage from any site in the body</h5> <p>Four studies (1245 participants) reported on bleeding (<a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). We decided not include <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> in the meta‐analysis because the study authors reported bleeding as oozing. We observed no evidence of a difference in bleeding between heparin and normal saline groups (RR 1.54, 95% CI 0.41 to 5.74; 3 studies, 1197 participants; P = 0.52; <a href="./references#CD008462-fig-0010" title="">Analysis 3.3</a>). <a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a> reported four and three bleeding events in heparin and normal saline groups, respectively. <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> reported no haemorrhages in any group. In <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>, one participant in the heparin group presented with bleeding versus none in the normal saline group (Chi² = 0; P = 0.984; Yates correction). We judged the certainty of evidence to be very low. We downgraded the certainty of evidence by three levels, i.e. one level due to risk of bias and two levels due to imprecision (low number of events and CIs were very wide). </p> <p><a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> reported oozing from the exit site of the dialysis catheter in five participants in the heparin group and in five in the normal saline group with no statistically significant differences (Chi² = 0.088; P = 0.799). </p> </section> <section id="CD008462-sec-0060"> <h5 class="title">Heparin‐induced thrombocytopaenia (HIT)</h5> <p>Three studies (443 participants) reported on HIT (<a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). Neither <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> nor <a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a> found cases of HIT. <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a> detected two cases, both in the normal saline group. Pooling data showed no clear evidence of an effect (RR 0.21, 95% CI 0.01 to 4.27; P = 0.31; <a href="./references#CD008462-fig-0011" title="">Analysis 3.4</a>). We judged the certainty of evidence as very low. Only one study detected HIT (<a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>), with a finding that is counterintuitive (lower detection of HIT in patients treated with heparin locking). We downgraded the certainty of evidence by three levels, i.e. one level due to risk of bias and two levels due to imprecision (low number of events and CIs were very wide). </p> </section> <section id="CD008462-sec-0061"> <h5 class="title">CVC‐related thrombosis</h5> <p>Only three studies (1527 participants) reported on the incidence of CVC‐related thrombosis (<a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a>; <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>). Pooled results showed no evidence of a difference in effect between heparin and normal saline groups (RR 1.24, 95% CI 0.77 to 2.02; P = 0.38; <a href="./references#CD008462-fig-0012" title="">Analysis 3.5</a>). </p> <p><a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a> found 10.7% had venous thromboembolism in the normal saline group (16 participants) and 13.1% (19 participants) in the heparin group (Chi² = 0.419; P = 0.518), with no statistical differences between groups. <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> found a confirmed diagnosis of central venous thrombosis in 13 participants (3.3%) in the heparin group and in 11 participants (2.8%) in the normal saline group (Chi² = 0.060; P = 0.807), retrospectively. <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a> reported one thrombosis in the heparin group. </p> <p>We judged the certainty of evidence to be low. We downgraded the certainty of evidence by two levels due to imprecision, i.e. low number of events and CIs were very wide. </p> </section> <section id="CD008462-sec-0062"> <h5 class="title">Number of additional CVC insertions</h5> <p>None of the included studies provided data on this outcome.</p> </section> <section id="CD008462-sec-0063"> <h5 class="title">Abnormality of coagulation profile</h5> <p>Only <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> reported alterations in coagulation parameters. These investigators studied activated coagulation time (ACT), activated partial thromboplastin time (APTT), and prothrombin time (PT). <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> reported differences between groups for both ACT (P &lt; 0.001) and APTT (P = 0.001). In particular, these parameters, except PT (P = 0.187), were higher in the heparin group. Differences observed in the PT parameter, which was elevated in the heparin group, did not reach statistical significance. </p> </section> <section id="CD008462-sec-0064"> <h5 class="title">Allergic reactions to heparin</h5> <p>None of the included studies provided data on this outcome.</p> </section> </section> <section id="CD008462-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses affecting main outcomes (occlusions) for published versus unpublished studies, for quality of studies, and for the weight of studies, as well as for choice of summary effects measure, odds ratio (OR) versus RR. </p> <p>The only study initially identified as an unpublished study was <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>, but this study was later published, and we identified no other unpublished studies. So, we could not perform this kind of predefined sensitivity analysis. </p> <p>We found that results for occlusion in the 10 studies with unit of analysis participant or catheter showed fewer occlusions with heparin (RR 0.70, 95% CI 0.51 to 0.95; P = 0.02; <a href="./references#CD008462-fig-0005" title="">Analysis 1.1</a>). This effect was lost when only studies with good allocation concealment were considered (RR 0.74, 95% CI 0.51 to 1.05; P = 0.09; <a href="./references#CD008462-fig-0013" title="">Analysis 4.1</a>). </p> <p>We explored the influence of studies contributing most to the effect estimate to assess whether a single study could reverse the direction of the effect. When we considered the outcome, occlusions of CVCs, with the unit of analysis, the participant, the study with the greatest weight was <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>. We performed a sensitivity analysis by removing this study from the analysis; it suggested a decrease in occlusions when using heparin (RR 0.52, 95% CI 0.30 to 0.91; P = 0.02; <a href="./references#CD008462-fig-0014" title="">Analysis 4.2</a>) compared with no clear difference between heparin and saline solution with the inclusion of <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> (RR 0.79, 95% CI 0.58 to 1.08; P = 0.15; <a href="./references#CD008462-fig-0005" title="">Analysis 1.1</a>). </p> <p>We explored and calculated differences between the OR and RR but found no evidence of a difference between measures (results not shown). </p> <p>We also explored the effect size in occlusions and patency. Here we standardised the results, so they were independent of the unit of analysis. We did this because there was discussion in our review authors group about whether it was appropriate to combine studies that used the participant as the unit of analysis with studies that used the catheter as the unit of analysis. Overall, the team concluded that it was reasonable to do so because most participants only ever have one catheter and, therefore, the two approximated to each other. However, we presented each unit of analysis also as a subgroup (<a href="./references#CD008462-fig-0005" title="">Analysis 1.1</a>). A different strategy for meta‐analysing results that are addressing the same underlying construct but measuring this construct in different ways is to standardise the results by converting them to an effect size, that is, a '<b>z</b>‐score' of a standard normal distribution. We did this in the sensitivity analysis in case readers of the review disagreed with our pragmatic approach in <a href="./references#CD008462-fig-0005" title="">Analysis 1.1</a>. </p> <p>Using <b>z</b>‐scores, we noted fewer occlusions with heparin (RR 0.78, 95% CI 0.62 to 0.98; 10 studies, 2697 participants; P = 0.04; <a href="./references#CD008462-fig-0015" title="">Analysis 4.3</a>), which was similar to the results shown in <a href="./references#CD008462-fig-0005" title="">Analysis 1.1</a> by unit of analysis participants and catheter. For completeness, we have also presented the effect size for occlusions by the original unit of analysis of the participant (RR 0.84, 95% CI 0.65 to 1.08) and catheter (RR 0.54, 95% CI 0.31 to 0.96), with no clear differences between them (P = 0.17; <a href="./references#CD008462-fig-0015" title="">Analysis 4.3</a>). </p> <p>We also assessed the effect of duration of patency using <b>z</b>‐scores, noting no clear difference between heparin and normal saline groups (MD 0.44, 95% CI ‐0.10 to 0.99; P = 0.11; <a href="./references#CD008462-fig-0016" title="">Analysis 4.4</a>), which was similar to <a href="./references#CD008462-fig-0007" title="">Analysis 2.1</a>. For completeness, we have also presented the effect size for duration of patency by the original unit of analysis of the participant (RR 0.66, 95% CI ‐0.66 to 1.97) and catheter (RR 0.40, 95% CI ‐0.20 to 0.99), with no clear differences between them (P = 0.72; <a href="./references#CD008462-fig-0016" title="">Analysis 4.4</a>). </p> </section> <section id="CD008462-sec-0066"> <h4 class="title">Subgroup analysis</h4> <p>We planned to perform subgroup analyses by type of participant, CVC site and CVC type, and perfusion‐related factors. We carried out subgroup analysis by oncology/non‐oncology patients, number of CVC lumens, heparin concentration used, and time to follow‐up. Data were insufficient for analysis by CVC implantation site or CVC type subgroup. We carried out subgroup analyses by the unit of analysis and reported these results above under the relevant outcomes. Given the small number of studies in the subgroups, the results should be interpreted with caution. </p> <p>Subgroup analysis to investigate occlusion in oncology and non‐oncology patients showed differences between groups. Occlusions in non‐oncology participants were different from those in oncology participants (RR 0.48, 95% CI 0.30 to 0.77; P = 0.002; vs RR 0.91, 95% CI 0.69 to 1.19; P = 0.48; respectively), favouring heparin use in non‐oncology participants (test for subgroup differences P = 0.02; <a href="./references#CD008462-fig-0017" title="">Analysis 5.1</a>). </p> <p>Subgroup analysis to assess the relationship between occlusion and the number of CVC lumens (unit of analysis ‐ participants) showed no clear differences between groups: occlusions in studies using CVCs with one lumen (RR 0.85, 95% CI 0.57 to 1.26) versus those using CVCs with more than one lumen (RR 0.63, 95% CI 0.15 to 2.59) (test for subgroup differences P = 0.69; <a href="./references#CD008462-fig-0018" title="">Analysis 5.2</a>). </p> <p>Subgroup analysis to investigate the effect of heparin concentration on occlusion showed no clear differences between high (≥ 1000 IU/mL) and low concentrations (&lt; 1000 IU/mL). According to heparin concentration, high concentrations (RR 0.41, 95% CI 0.14 to 1.25) versus low concentrations (RR 0.65, 95% CI 0.31 to 1.34) showed no clear differences (test for subgroup differences P = 0.50; <a href="./references#CD008462-fig-0019" title="">Analysis 5.3</a>). </p> <p>We performed subgroup analysis to assess whether occlusions were related to time to follow‐up. When time to follow‐up was less than one month, we found differences favouring heparin (RR 0.48, 95% CI 0.30 to 0.77). When time to follow‐up was one month or longer, we noted no clear differences (RR 0.91, 95% CI 0.69 to 1.19). Testing for subgroup differences showed differences between the subgroups (P = 0.02; <a href="./references#CD008462-fig-0020" title="">Analysis 5.4</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008462-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008462-sec-0067"></div> <section id="CD008462-sec-0068"> <h3 class="title" id="CD008462-sec-0068">Summary of main results</h3> <p>The aim of the present update was to assess the effectiveness of intermittent locking with heparin versus normal saline in adults with CVCs in terms of prevention of occlusion and overall benefits versus harms. CVCs are frequently used to provide blood derivatives, medication, or nutritional support to patients, as well as for diagnostic monitoring, cardiac pacing, and other procedures. However, their use could result in thrombosis and infection and may prolong hospital stay. </p> <p>Low‐certainty evidence suggests that, in adults, intermittent locking of CVCs with heparin may show a slight reduction of occlusions than intermittent locking with normal saline. </p> <p>Low‐certainty evidence suggests that heparin has little or no effect on the duration of catheter patency. Although we did not detect any clear differences in safety, the trials that were combined are not sufficiently powered to detect rare adverse events, such as HIT. Lack of an effect of heparin concentration and the suggestion of publication bias as demonstrated by the funnel plot mean that these results should be interpreted cautiously. These findings on efficacy (occlusion and patency) could be related to the types of participants included (subgroup analysis indicated there may be more benefit for non‐oncology patients) and to the methodological quality of trials (effect changed when studies with appropriate allocation concealment were included in sensitivity analysis). The certainty of the evidence ranged from low to very low. </p> </section> <section id="CD008462-sec-0069"> <h3 class="title" id="CD008462-sec-0069">Overall completeness and applicability of evidence</h3> <p>All addressed outcomes were examined. Statistical heterogeneity was low (I² = 0) for the main outcomes of efficacy (occlusion and patency) and safety (bleeding, thrombosis, and mortality), despite inclusion of participants with very different conditions (admitted to the intensive care units, with onco‐haematological malignancies, or undergoing haemodialysis), treated with a very wide range of heparin concentrations ranging from 10 IU/mL to 5000 IU/mL. Only CVC‐related bloodstream infections showed statistical heterogeneity (I² = 56%), which could be explained by the different clinical conditions of participants in the three studies reporting CVC‐related bloodstream infections. </p> <p>Our results are consistent with those of a retrospective cohort study by <a href="./references#CD008462-bbs2-0224" title="JonkerMA , OsterbyKR , VermeulenLC , KleppinSM , KudskKA . Does low-dose heparin maintain central venous access device patency? A comparison of heparin versus saline during a period of heparin shortage. Journal of Parenteral and Enteral Nutrition2010;34(4):444-9. [PMID: 20631392]">Jonker 2010</a>, which detected increased use of alteplase to manage catheter obstructions flushed with normal saline compared with catheters locked with heparin. However, these results may be biased by the indirectness of outcomes. </p> <p>It is interesting to consider also the use of systemic anticoagulants among different studies. In <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> and <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a>, use of any anticoagulation was a criterion of exclusion; although some studies provided either no data on permitted use of systemic anticoagulation in every participant (<a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>; <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a>), or in only some participants (<a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a>; <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>), differences were found to be not significant. Moreover, <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a> excluded patients with intolerance to heparin, and <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a> excluded patients with risk of bleeding. However, the exclusion of <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> and <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> ‐ two studies that used the exclusion criterion of use of anticoagulants ‐ resulted in no change in findings of the sensitivity analysis. </p> <p>The length of follow‐up for safety in this review could be too short to reveal relevant adverse events. Only <a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a> (231 days) and <a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> (180 days) provided long‐term follow‐up, whereas <a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a>, <a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a>, <a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a>, <a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a>, <a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a>, <a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a> and <a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a> studied participants for a shorter time ranging from 24 hours to 23 days. <a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a>, <a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> and <a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a> studied participants for a period ranging from 40 to 90 days. Consequently, the potential for higher incidence of adverse events with long‐term follow‐up cannot be discarded. Given that CVCs could be placed for several months according to the needs of patients, adverse events may be more relevant than those described in the present systematic review. None of the 12 included trials planned to study adverse events as a primary outcome. It cannot be ruled out that adverse events may occur with longer exposure or larger numbers of participants. </p> <p>Despite results suggesting no differences in safety, it is probable that a high proportion of patients could be at increased risk with heparin use. This increased risk of adverse events due to heparin locking may be especially relevant among patients with liver or kidney failure and those with recent surgery (especially of the brain, eye, or spine), spinal anaesthesia, or recent injury. Also, patients who have a history of heart problems, high blood pressure, menstrual problems, bleeding problems, or a history of ulcers or other stomach problems, or who are taking drugs such as non‐steroidal anti‐inflammatory drugs or antiplatelet agents, may have an increased risk of bleeding. Adverse events may be reduced by flushes with normal saline. </p> <p>Heparin‐induced thrombocytopaenia (HIT) is an adverse event that may be life‐threatening. It is more common after intraoperative or perioperative administration of heparin. Its incidence is reported at between 0.1% and 5%. Risk factors for HIT include type of heparin used (greater risk with unfractionated heparin), duration of exposure, patient setting, and patient gender (1.5 to 2 times higher among women) (<a href="./references#CD008462-bbs2-0208" title="BattistelliS , GenoveseA , GoriT . Heparin-induced thrombocytopenia in surgical patients. American Journal of Surgery2010;199(1):43-51.">Battistelli 2010</a>). In general, higher doses of heparin result in a greater risk of HIT. However, lower heparin doses used to flush catheters have occasionally been associated with HIT (<a href="./references#CD008462-bbs2-0232" title="McNultyI , KatzE , KimKY . Thrombocytopenia following heparin flush. Progress in Cardiovascular Nursing2005;20(4):143-7.">McNulty 2005</a>). In the present systematic review, HIT was not reported in the heparin groups, and only two cases were reported in the normal saline groups (<a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a>), suggesting altogether an undiagnosed adverse event. </p> <p>It should be mentioned that some outcomes (i.e. bleeding, occlusion, thrombosis) of the present review were either not properly defined or not defined at all in the included studies. Similarly, the sampling times for the outcome patency are not clearly established in the studies. Notwithstanding these clear limitations, the present review had to accept and analyse the data as were de facto reported in the included studies. It is unfeasible to assess how this required assumption may have affected the reported outcomes. </p> </section> <section id="CD008462-sec-0070"> <h3 class="title" id="CD008462-sec-0070">Quality of the evidence</h3> <p>We have presented the main results in <a href="./full#CD008462-tbl-0001">summary of findings Table 1</a>. The certainty of evidence ranged from very low to low. </p> <p>The certainty of evidence for the main outcome (all occlusions of CVC) was low. We downgraded the certainty of evidence by one level for risk of bias due to suspicion of publication bias and one more level for imprecision. Although the common rule is not to create a funnel plot for fewer than 10 studies, we created it because the included studies described different effects and different sizes. Although other possible sources of asymmetry can be addressed (selection bias, poor method, artefacts, or chance), we cannot discard the possibility of publication bias. </p> <p>We judged the certainty of evidence for overall duration of catheter patency as low. We judged the certainty of evidence as low. We downgraded the certainty of evidence by one level for risk of bias due to unclear allocation concealment and by one more level for imprecision. </p> <p>We judged the certainty of evidence for CVC‐related bloodstream infections to be very low. We downgraded the certainty of evidence by two levels due to imprecision (low number of events and CIs were very wide) and one more level due to inconsistency. </p> <p>We judged the certainty of evidence for mortality to be very low. We downgraded the certainty of evidence by three levels, i.e. one level due to risk of bias and two levels due to imprecision (low number of events and CIs were very wide). </p> <p>We judged the certainty of evidence for haemorrhage from any site to be very low. We downgraded the certainty of evidence by three levels, i.e. one level due to risk of bias and two levels due to imprecision (low number of events and CIs were very wide). </p> <p>We judged the certainty of evidence for HIT to be very low. We downgraded the certainty of evidence by three levels, i.e. one level due to risk of bias and two levels due to imprecision (low number of events and CIs were very wide). </p> <p>We did not include the secondary outcomes CVC‐related thrombosis and abnormality of the coagulation profile in <a href="./full#CD008462-tbl-0001">summary of findings Table 1</a>. We judged the certainty of evidence for CVC‐related thrombosis to be low. We downgraded the certainty of evidence by two levels due to imprecision, i.e. low number of events and CIs were very wide. We did not judge the certainty of evidence for abnormality of the coagulation profile because only one study provided information on this outcome. </p> <p>In summary, risk of bias for unclear allocation concealment and imprecision were the criteria that downgraded the certainty of evidence for most outcomes, and risk of publication bias for the outcome 'all occlusions'. </p> </section> <section id="CD008462-sec-0071"> <h3 class="title" id="CD008462-sec-0071">Potential biases in the review process</h3> <p>Review authors carried out study selection and data extraction in a duplicate manner. We published a protocol for this systematic review (<a href="./references#CD008462-bbs2-0252" title="López-BrizE , Ruiz GarciaV , CabelloJB , Bort-MartiS , Carbonell SanchisR , BurlsA . Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD008462. [DOI: 10.1002/14651858.CD008462]">López‐Briz 2010</a>). None of the authors of this review update was involved in any of the included or excluded studies. We selected a priori all outcomes analysed. We contacted trial authors and retrieved additional information. Hence, the probability of publication bias among studies included in this systematic review is low. However, we could not discard the possibility of bias from non‐published studies after we assessed the funnel plot for publication bias (<a href="./full#CD008462-fig-0001">Figure 1</a>). </p> <p>For the unit of analysis of participant or catheter, heparin showed a small benefit. We concluded that it was reasonable to pool both units of analysis because most participants only ever have one catheter, and therefore the two approximated to each other. This was an 'a posteriori' decision, and it must be kept in mind when review results are interpreted. We carried out additional analyses to check the robustness of this decision. </p> </section> <section id="CD008462-sec-0072"> <h3 class="title" id="CD008462-sec-0072">Agreements and disagreements with other studies or reviews</h3> <p>Other systematic reviews focused on heparin use in CVCs have used different inclusion and/or exclusion criteria from those of this review. <a href="./references#CD008462-bbs2-0239" title="RandolphAG , CookDJ , GonzalesCA , AndrewM . Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials. Chest1998;113(1):165-71.">Randolph 1998b</a> reviewed randomised controlled trials in adult and paediatric participants in whom heparin was infused continuously through the catheter, administered subcutaneously (SC), or bonded to the catheter. They found a trend toward a reduction in catheter thrombus and a significant reduction (57%) in venous thrombosis. Statistical heterogeneity was not significant in both cases. Heparin dosage ranged from SC 5000 IU every 12 hours to 1 IU/mL in continuous perfusion added to total parenteral nutrition. </p> <p><a href="./references#CD008462-bbs2-0225" title="KlerkCPW , SmorenburgSM , BüllerHR . Thrombosis prophylaxis in patient populations with a central venous catheter. Archives of Internal Medicine2003;163(16):1913-21.">Klerk 2003</a> also reviewed studies with adult and paediatric participants with CVCs in whom heparin flushes or antithrombotic agents were administered in prophylactic or therapeutic doses. This review concluded that heparin added to parenteral nutrition did not significantly decrease the risk of catheter‐related thrombosis. However, this review cannot be compared with the present one because it differed in the design of included studies (randomised controlled trials and prospective cohort studies) and in the intervention provided (systemic heparin). </p> <p>A previous systematic review conducted by some of the authors of this Cochrane review found and included only two studies, one of which included paediatric participants (<a href="./references#CD008462-bbs2-0229" title="López-BrizE , Ruiz-GarciaV . Effectiveness of heparin versus NaCl 0.9% in central venous catheter flushing. A systematic review [Heparina frente a cloruro sódico 0.9% para mantener permeables los catéteres venosos centrales. Una revisión sistemática]. Farmacia Hospitalaria2005;29(4):258-64.">López‐Briz 2005</a>). Results showed no differences between heparin and normal saline locking. </p> <p><a href="./references#CD008462-bbs2-0236" title="MitchellMD , AndersonBJ , WilliamsK , UmscheidCA . Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. Journal of Advanced Nursing2009;65(10):2007-21.">Mitchell 2009</a> conducted a systematic review focussed on adult participants with CVCs or PICCs comparing heparin locking, continuous heparin perfusion, normal saline locking, urokinase locking, and heparin‐bonded catheter versus any other intervention. The review authors concluded that "there is insufficient evidence on which to find that flushing catheters with heparin are more effective than flushing with saline solution" (<i>verbatim</i>). </p> <p>In paediatric participants, <a href="./references#CD008462-bbs2-0241" title="ShahPS , ShahVS . Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD002772. [DOI: 10.1002/14651858.CD002772.pub3]">Shah 2008</a> found that continuous heparin infusion reduced the risk of catheter occlusion with no statistically significant differences in the duration of catheter patency. However, the review authors could not provide recommendations for heparin use in neonates with PICCs. These review authors detected high clinical heterogeneity and high heterogeneity in treatment effect. </p> <p>Guidelines have led to a wide variety of locking protocols, with many different types of locking solutions, volumes, locking frequencies, and heparin concentrations because these guidelines are based mainly on manufacturers' recommendations ‐ not on published evidence (<a href="./references#CD008462-bbs2-0236" title="MitchellMD , AndersonBJ , WilliamsK , UmscheidCA . Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review. Journal of Advanced Nursing2009;65(10):2007-21.">Mitchell 2009</a>; <a href="./references#CD008462-bbs2-0243" title="SonaC , PrenticeD , SchallomL . National survey of central venous catheter flushing in the intensive care unit. Critical Care Nurse2012;32(1):e12-9.">Sona 2012</a>). The Infusion Therapy Standards of Practice of 2016 (<a href="./references#CD008462-bbs2-0222" title="GorskiLA . INS Learning Center: infusion therapy standards of practice 2016. learningcenter.ins1.org/products/infusion-therapy-standards-of-practice-2016 (accessed 9 May 2017).">INS 2016</a>), and the updated version of 2021 (<a href="./references#CD008462-bbs2-0216" title="GorskiLA , HadawayL , HagleME , BroadhurstD , ClareS , KleidonT , et al. Infusion therapy standards of practice, 8th edition. Journal of Infusion Nursing2021;44(1S Suppl 1):S1-S224. [DOI: 10.1097/NAN.0000000000000396]">Gorski 2021</a>) are in line with the conclusions of our SR ("Use of 0.9% sodium chloride alone may be as effective as heparin in locking to maintain port patency" (<i>verbatim</i>)). <a href="./references#CD008462-bbs2-0244" title="SousaB , FurlanettoJ , HutkaM , GouveiaP , WuerstleinR , MarizJM , et al. Central venous access in oncology: ESMO Clinical Practice Guidelines. Annals of Oncology2015;26(Suppl 5):v152-68.">Sousa 2016</a> stated that "Intermittent flushing with heparin is a standard practice in the maintenance of CVC patency. However, when compared with 0.9% normal saline flushing, no differences in thrombosis rates were found" (<i>verbatim</i>). Finally, <a href="./references#CD008462-bbs2-0226" title="KovacevichDS , CorriganM , RossVM , McKeeverL , HallAM , BraunschweigC . American Society for parenteral and enteral nutrition guidelines for the selection and care of central venous access devices for adult home parenteral nutrition administration. Journal of Parenteral and Enteral Nutrition2019;43(1):15-31.">Kovacevich 2019</a> reported from the American Society for Parenteral and Enteral Nutrition (ASPEN) clinical guidelines to describe best practices in the selection and care of central venous access devices (CVADs) for the infusion of home parenteral nutrition (HPN) admixtures in adult patients. The flushing protocols compared were normal saline, heparin 10 IU/mL, and heparin 100 IU/mL. Although the "results indicated that the saline‐only group required additional home RN [? registered nurse] visits to assess for sluggishness/occlusions (32.1% compared with 15.6% for the 100 U/mL and 13.3% for the 10 U/mL; P = 0.150)", the authors concluded that "there is no strong evidence to support the use of heparin vs saline flush solutions to maintain CVAD patency" (<i>verbatim</i>). The results are in line with those of our review, although the conclusion is slightly different. The authors reported only a trend in the results towards significance that, according to them, reflected "the small sample sizes". </p> <p>Various systematic reviews reported no differences. <a href="./references#CD008462-bbs2-0213" title="Dal MolinA , AllaraE , MontaniD , MilaniS , FrassatiC , CossuS , et al. Flushing the central venous catheter: is heparin necessary?Journal of Vascular Access2014;15(4):241-8.">Dal Molin 2014</a> performed a network meta‐analysis and concluded: "There is no evidence of a different effectiveness between heparin flushing and normal saline or other solutions in reducing catheter occlusions" (<i>verbatim</i>). </p> <p>The systematic review of <a href="./references#CD008462-bbs2-0249" title="WenZ , ShenM , ZhangH , LiuQ , WangZ . Flushing effects of normal saline and heparin saline after central venous catheterization: a meta-analysis [Chinese]. Chinese Journal of Evidence-Based Medicine2017;17(1):58-64.">Wen 2017</a> presented similar findings to this review, namely, no significant differences in occlusion rate (OR 1.58, 95%CI 0.79 to 3.14, P = 0.19) and duration of catheter days (OR –7.24, 95%CI –22.90 to 8.41, P = 0.36), while the heparin group had more advantage than the normal saline group in decreasing the incidence of phlebitis (OR 2.57, 95%CI 1.52 to 4.34, P = 0.0004). </p> <p><a href="./references#CD008462-bbs2-0251" title="ZhongL , WangHL , XuB , YuanY , WangX , ZhangYY , et al. Normal saline versus heparin for patency of central venous catheters in adult patients - a systematic review and meta-analysis. Critical Care2017;21(1):5. [PMID: 28063456]">Zhong 2017</a> concluded that heparin locking is not superior to saline in the maintenance of CVC lumen catheters. In a post hoc analysis, these review authors suggested that heparin could be effective when used with follow‐up of less than one month. We found the same data but noted a lack of plausibility only about this time‐limited effect. A similar Cochrane systematic review was carried out in paediatric patients and concluded: "It remains unclear whether heparin is necessary to prevent occlusion, CVC‐associated bloodstream infection or effects duration of catheter placement" (<a href="./references#CD008462-bbs2-0211" title="BradfordNK , EdwardsRM , ChanRJ . Normal saline (0.9% sodium chloride) versus heparin intermittent flushing for the prevention of occlusion in long-term central venous catheters in infants and children. Cochrane Database of Systematic Reviews2020, Issue 4. Art. No: CD010996. [DOI: 10.1002/14651858.CD010996.pub3]">Bradford 2020</a>). <a href="./references#CD008462-bbs2-0196" title="WoutersY , CausevicE , KlekS , GroenewoudH , WantenGJ . Use of catheter lock solutions in patients receiving home parenteral nutrition: a systematic review and individual-patient data meta-analysis. Journal of Parenteral and Enteral Nutrition2020;44(7):1198-209. ">Wouters 2020</a> reported a systematic review that focussed on the prevention of catheter‐related bloodstream infections (CRBSI) in patients receiving home parenteral nutrition. The review concluded that taurolidine was more effective than saline or heparin flushing: the cumulative proportion of CRBSI‐free patients using taurolidine, saline, and heparin after one year was 88%, 56%, and 14%, respectively. Our review does not support this finding. <a href="./references#CD008462-bbs2-0250" title="WuXH , ChenLC , LiuGL , ZhangTT , ChenXS . Heparin versus 0.9% saline solution to maintain patency of totally implanted venous access ports in cancer patients: a systematic review and meta-analysis. International Journal of Nursing Practice2021;27(2):e12913.">Wu 2021</a> reported a systematic review that focussed on whether saline solution can replace heparin solution in totally implantable venous access ports (TIVAPs) in adult cancer patients. The review recommended that saline solution can replace 50 or 100 IU/mLl of heparin as a safe and effective flush solution for TIVAPs. </p> <p>Overall, the above systematic reviews suggest a protective effect for occlusions with heparin, but without statistical significance. Our review update has included more trials and more participants. Our results regarding benefits with heparin use are uncertain. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008462-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Occlusion of CVCs, outcome: 1.1 All studies" data-id="CD008462-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Occlusion of CVCs, outcome: 1.1 All studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram 2021" data-id="CD008462-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram 2021</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008462-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008462-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Occlusion of CVCs, Outcome 1: All studies" data-id="CD008462-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Occlusion of CVCs, Outcome 1: All studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Occlusion of CVCs, Outcome 2: Unit of analysis: line access" data-id="CD008462-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Occlusion of CVCs, Outcome 2: Unit of analysis: line access</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Duration of catheter patency (days), Outcome 1: All studies" data-id="CD008462-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Duration of catheter patency (days), Outcome 1: All studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Safety, Outcome 1: CVC‐related bloodstream infections" data-id="CD008462-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Safety, Outcome 1: CVC‐related bloodstream infections</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Safety, Outcome 2: Mortality" data-id="CD008462-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Safety, Outcome 2: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Safety, Outcome 3: Haemorrhage from any site" data-id="CD008462-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Safety, Outcome 3: Haemorrhage from any site</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Safety, Outcome 4: Heparin‐induced thrombocytopaenia" data-id="CD008462-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Safety, Outcome 4: Heparin‐induced thrombocytopaenia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Safety, Outcome 5: CVC‐related thrombosis" data-id="CD008462-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Safety, Outcome 5: CVC‐related thrombosis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis, Outcome 1: Occlusion of CVCs ‐ good allocation concealment" data-id="CD008462-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis, Outcome 1: Occlusion of CVCs ‐ good allocation concealment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis, Outcome 2: Occlusion of CVCs ‐ excluding most weighted study (Goosens 2013)" data-id="CD008462-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis, Outcome 2: Occlusion of CVCs ‐ excluding most weighted study (Goosens 2013) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis, Outcome 3: Occlusion of CVCs ‐ Z scores by unit of analysis" data-id="CD008462-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis, Outcome 3: Occlusion of CVCs ‐ Z scores by unit of analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis, Outcome 4: Duration of catheter patency ‐ Z scores by unit of analysis" data-id="CD008462-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis, Outcome 4: Duration of catheter patency ‐ Z scores by unit of analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Additional subgroup analysis, Outcome 1: Oncology vs non‐oncology participants: occlusion of CVCs" data-id="CD008462-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Additional subgroup analysis, Outcome 1: Oncology vs non‐oncology participants: occlusion of CVCs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Additional subgroup analysis, Outcome 2: One vs more than one lumen (unit of analysis is participant): occlusion of CVCs" data-id="CD008462-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Additional subgroup analysis, Outcome 2: One vs more than one lumen (unit of analysis is participant): occlusion of CVCs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Additional subgroup analysis, Outcome 3: High vs low heparin concentration: occlusion of CVCs" data-id="CD008462-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Additional subgroup analysis, Outcome 3: High vs low heparin concentration: occlusion of CVCs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008462-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/urn:x-wiley:14651858:media:CD008462:CD008462-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Additional subgroup analysis, Outcome 4: Less than one month vs over one month follow‐up: occlusion of CVCs" data-id="CD008462-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_t/tCD008462-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Additional subgroup analysis, Outcome 4: Less than one month vs over one month follow‐up: occlusion of CVCs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/media/CDSR/CD008462/image_n/nCD008462-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008462-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus normal saline solution locking for prevention of occlusion in central venous catheters in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Heparin versus normal saline solution locking for prevention of occlusion in central venous catheters in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with CVCs<br/><b>Settings:</b> hospital<br/><b>Intervention:</b> heparin<br/><b>Comparison:</b> normal saline solution (0.9% NaCl) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects * (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with normal saline</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p>Risk with h<b>eparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Occlusion of CVC</b> </p> <p><b>(combining participant, and catheter as unit of analysis)</b> </p> <p>Blood withdrawing<br/>Follow‐up: 1 to 231 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.70</b> <br/>(0.51 to 0.95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1672 participants,</p> <p>1025 catheters<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heparin may reduce the rate of CVC occlusion when compared to normal saline, NNTB: 42 (95% CI 32 to 252). </p> <p>Considering only participant as unit of analysis:</p> <p>RR 0.79 (95% CI 0.58 to 1.08; 7 studies, 1672 participants)</p> <p>Considering only catheter as unit of analysis:</p> <p>RR 0.53 (95% CI 0.29 to 0.95; 3 studies, 1025 catheters), NNTB: 35 (95% CI 23 to 326)</p> <p>Considering only line access as unit of analysis:</p> <p>RR 1.06 (95% CI 0.84 to 1.33; 2 studies, 6835 lines accessed)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>103 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/><b>(62 to 86)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Duration of catheter patency</b> </p> <p><b>(days; combining participant and catheter as unit of analysis)</b> </p> <p>Blood withdrawing<br/>Follow‐up: 3 to 180 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1788<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in duration of catheter patency was shown ‐ less than 1 day longer with heparin locking </p> <p>Considering only participant as unit of analysis:</p> <p>MD 0.66 (95% CI ‐0.66 to 1.97; 4 studies, 1036 participants)</p> <p>Considering only catheter as unit of analysis:</p> <p>MD 0.40 (95% CI ‐0.20 to 0.99; 2 studies, 752 catheters)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean catheter patency in the normal saline group was</p> <p>9 days (8.36 to 9.7 days)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean catheter patency in the heparin group was <b>0.44 days more</b> <br/><b>(‐0.1 less to 0.99 more)</b> than in the normal saline group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>CVC‐related bloodstream infections (positive microbiological culture, participant as unit of analysis)</b> </p> <p>Follow‐up: 22 to 180 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.66</b><br/>(0.08 to 5.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1127<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in CVC‐related bloodstream infections between locking methods was shown. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> <br/><b>(0 to 212)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>Follow‐up: 17 to 180 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b> <br/>(0.44 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1100<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in mortality between locking methods was shown.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> <p><b>(24 to 57)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Haemorrhage from any site</b><br/>Follow‐up: 1 to 180 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR</b> 1.54 </p> <p>95% CI 0.41 to 5.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1197<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in haemorrhage between locking methods was shown.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> <br/><b>(‐10 to 11)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Heparin‐induced thrombocytopaenia</b> </p> <p>Follow‐up: 7 to 22 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.21</b> </p> <p>(0.01 to 4.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>443</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No clear evidence of a difference in HIT between locking methods was shown. Studies are likely to be underpowered to detect low adverse events. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> <p><b>(0 to 38)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>**<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>CVC</b> : central venous catheter; <b>HIT</b> : heparin‐induced thrombocytopaenia; <b>MD</b> : mean difference; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> We downgraded the certainty of evidence by two levels, i.e. one level for risk of bias due to suspicion of publication bias (see <a href="./full#CD008462-fig-0001">Figure 1</a>) and one level due to imprecision.<br/><sup>2</sup> We downgraded the certainty of evidence by two levels, i.e. one level for risk of bias due to unclear allocation concealment and one level due to imprecision.<br/><sup>3</sup> We downgraded the certainty of evidence by three levels, i.e. two levels due to imprecision (low number of events and CIs were very wide) and one level due to inconsistency.<br/><sup>4</sup> We downgraded the certainty of evidence by three levels, i.e. one level due to risk of bias and two levels due to imprecision (low number of events and CIs were very wide). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus normal saline solution locking for prevention of occlusion in central venous catheters in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008462-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Secondary outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>CVC‐related thrombosis</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>CVC‐related bloodstream infections</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Mortality</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>HIT</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NS</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>H</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NS</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0001" title="BabuBM , RaoAK , RajeshK , BabuVH . Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomised trial. Journal of Evolution of Medical and Dental Sciences2014;3(1):46-51. ">Babu 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0002" title="BeigiAK , HadiZadehMS , SalimiF , GhaheriH . Heparin compared with normal saline to maintain patency of permanent double lumen hemodialysis catheters: a randomized controlled trial. Advanced Biomedical Research2014;3:121. [DOI: 10.4103/2277-9175.133192]">Beigi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0003" title="BowersL , SperoniKG , JonesL , AthertonM . Comparison of occlusion rates by flushing solutions for peripherally inserted central catheters with positive pressure Luer-activated devices. Journal of Infusion Nursing2008;31(1):22-7. ">Bowers 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0004" title="Dal MolinA , ClericoM , BacciniM , GuerrettaL , SartorelloB , RaseroL . Normal saline versus heparin solution to lock totally implanted venous access devices: results from a multicenter randomized trial. European Journal of Oncology Nursing2015;19(6):638-43. ">Dal Molin 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0005" title="GoossensGA , JérômeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Comparing normal saline versus diluted heparin to lock non-valved totally implantable venous access devices in cancer patients: a randomised, non-inferiority, open trial. Annals of Oncology2013;24(7):1892-9. GoossensGA , JeromeM , JanssensC , PeetermansWE , FieuwsS , MoonsP , et al. Heparin versus normal saline as locking solution in totally implantable venous ports: a randomized controlled trial in cancer patients. Supportive Care in Cancer2013;21:S28. ">Goosens 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0006" title="Heidari GorjiMA , RezaeiF , JafariH , Yazdani CheratiJ . Comparison of the effects of heparin and 0.9% sodium chloride solutions in maintenance of patency of central venous catheters. Anesthesiology and Pain Medicine2015;5(2):e22595. ">Heidari 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0007" title="KanekoY , IwanoM , YoshidaH , KosugeM , ItoS , NaritaI , et al. Natural saline-flush is sufficient to maintain patency of immobilized-urokinase double-lumen catheter used to provide temporary blood access for hemodialysis. Blood Purification2004;22(5):473-9. ">Kaneko 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0008" title="KleinJ , JepsenA , PattersonA , ReichRR , MasonTM . Heparin versus normal saline: flushing effectiveness in managing central venous catheters in patients undergoing blood and marrow transplantation. Clinical Journal of Oncology Nursing2018;22(2):199-202. KleinJ , PattersonA , JepsenA , BadgeroK , MooreM , WarrellWA , et al. Effectiveness of heparin versus saline flushing for managing central venous catheters (CVCs) in the blood and marrow transplant (BMT) patients: a pilot study. Biology of Blood and Marrow Transplantation2017;23(3 Suppl 1):S386. ">Klein 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0009" title="LyonsMG , PhalenAG . A randomized controlled comparison of flushing protocols in home care patients with peripherally inserted central catheters. Journal of Infusion Nursing2014;37(4):270-81. ">Lyons 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008462-bbs2-0010" title="PumarolaCF , MercaderRC , PlanaMC , BuenoCC , CasellasSS , VidalMF , et al. [Comparative study of maintenance of patency of triple lumen central venous catheter] [Estudio comparativo del mantenimiento de la permeabilidad de los cateteres venosos centrales de tres luces]. Enfermeria Intensiva2007;18(1):25-35. ">Pumarola 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008462-bbs2-0011" title="RabeC , GramannT , SonsX , BernaM , Gonzalez-CarmonaMA , KlehrHU , et al. Keeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients. Intensive Care Medicine2002;28(8):1172-6. ">Rabe 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008462-bbs2-0012" title="SchallomME , PrenticeD , SonaC , MicekST , SkrupkyLP . Heparin or 0.9% sodium chloride flush to maintain central venous catheter patency: a randomized trial. Critical Care Medicine2012;40(6):1820-6. ">Schallom 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/150</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>CVC: central venous catheter<br/>H: heparin<br/>HIT: heparin‐induced thrombocytopaenia<br/>NR: not reported<br/>NS: normal saline (0.9% NaCl) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Secondary outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/full#CD008462-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008462-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Occlusion of CVCs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.51, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Unit of analysis: participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.58, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Unit of analysis: catheter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.29, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Unit of analysis: line access <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.84, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Occlusion of CVCs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008462-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Duration of catheter patency (days)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.10, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Unit of analysis: participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐0.66, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Unit of analysis: catheter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.20, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Duration of catheter patency (days)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008462-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Safety</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 CVC‐related bloodstream infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.08, 5.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.44, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Haemorrhage from any site <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.41, 5.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Heparin‐induced thrombocytopaenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 CVC‐related thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.77, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Safety</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008462-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Occlusion of CVCs ‐ good allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Occlusion of CVCs ‐ excluding most weighted study (Goosens 2013) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.30, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Occlusion of CVCs ‐ Z scores by unit of analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.62, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Unit of analysis: participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.65, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Unit of analysis: catheter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.31, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Duration of catheter patency ‐ Z scores by unit of analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.10, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Unit of analysis: participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [‐0.66, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Unit of analysis: catheter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.20, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008462-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Additional subgroup analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Oncology vs non‐oncology participants: occlusion of CVCs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.51, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Non‐oncology participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.30, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Oncology participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.69, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 One vs more than one lumen (unit of analysis is participant): occlusion of CVCs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.68, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 One lumen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 More than one lumen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.15, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 High vs low heparin concentration: occlusion of CVCs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.32, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Heparin ≥ 1000 IU/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.14, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Heparin &lt; 1000 IU/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.31, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Less than one month vs over one month follow‐up: occlusion of CVCs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Less than one month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.30, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 One month or longer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.69, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Additional subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008462.pub4/references#CD008462-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008462.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008462-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008462-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008462-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008462-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD008462-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD008462-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008462-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008462\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008462\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008462\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008462\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008462\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008462.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008462.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008462.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008462.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008462.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718383993"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008462.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718383997"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008462.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dcf02e945935f',t:'MTc0MDcxODM4NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 